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ABSTRACT 
Kristina M. Reuille 
CANCER TREATMENT-RELATED FATIGUE: PSYCHOMETRIC TESTING OF 
THE CANCER TREATMENT-RELATED FATIGUE REPRESENTATION SCALE 
(CTRFREP) IN PATIENTS 
UNDERGOING RADIATION TREATMENT FOR CANCER 
Cancer treatment-related fatigue (CTRF) is recognized as a prevalent and 
bothersome symptom for patients with cancer. In a model of the CTRF experience, CTRF 
representation, or the beliefs, thoughts and emotions surrounding the experience of 
CTRF, is believed to mediate the relationship between CTRF intensity and CTRF 
distress. To date, there is no reported measure of CTRF representation. The purpose of 
this descriptive, cross-sectional study guided by Leventhal’s Common Sense Model of 
Self-Regulation was to evaluate an instrument designed to measure CTRF representation, 
the CTRF Representation scale (CTRFRep), based on an existing measure, the Illness 
Perception Questionnaire (IPQ-R). 
The study included 47 patients (mean age=57.7 years) receiving radiation therapy 
for cancer interviewed one month post-treatment. 77% of patients had fatigue during 
treatment. Three content experts and one theory expert assessed content validity of the 
CTRFRep. The content experts included three behavioral oncology nurse researchers 
whose focus is on symptom management and/or fatigue. The theory expert was a nurse 
researcher who is an expert in the area of self-regulation theory. As tested, the CTRFRep 
consisted of 105 items in 10 subscales addressing beliefs about the Identity, Timeline 
(Acute vs. Chronic/Cyclical), Consequences (positive/negative), Cause, Control 
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(Treatment/Personal), Symptom Coherence, and Emotional Representation of CTRF. 
When evaluating psychometrics, the Identity and Cause subscales are analyzed 
independent of the other subscales. For the Identity subscale, symptoms most reported as 
related to CTRF were lack of energy, loss of strength, and feeling blue. For the Cause 
subscale, the most common beliefs regarding causes of CTRF were cancer treatment(s), 
having cancer, and stress or worry. 
Results indicate adequate reliability in six of eight remaining subscales 
(α>=0.70); the item N in those subscales was reduced from 56 to 34. To address construct 
validity, logistic regression assessed whether CTRFRep mediated the relationship 
between CTRF intensity and CTRF distress. After controlling for negative affect, the 
Identity and Consequences subscales were significant mediators – the Acute vs. Chronic 
Timeline and Emotional Representation scales were partial mediators – of the 
relationship between CTRF intensity on CTRF distress. These findings indicate fatigue is 
a problem for people undergoing treatment for cancer, and the CTRFRep may be a 
reliable and valid measure of CTRF representation for patients undergoing radiation 
treatment for cancer. Small sample size prevented successful factor analysis of the 
CTRFRep. Further research of the CTRFRep is warranted. 
       
      Janet L. Welch, DNS, RN, Co-Chair 
 
       
      Juanita F. Keck, DNS, RN Co-Chair 
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CHAPTER 1: THE NATURE OF THE STUDY 
Introduction 
In 2009, nearly 1.5 million Americans will be diagnosed with cancer (American 
Cancer Society, 2009). Many of those diagnosed with cancer elect to receive treatment 
with surgery, radiation, and/or biotherapies with the hope of curing or controlling their 
disease. Although symptoms such as pain, nausea and depressive symptoms are common 
side-effects of cancer and its treatment, fatigue affects 61% to 96% of those undergoing 
treatment for cancer (Irvine, Vincent, Graydon, Bubela, & Thompson, 1994; Nail, Jones, 
Greene, Schipper, & Jensen, 1991; Nail & King, 1987; Schwartz, 1998). Many patients 
report that it is the most bothersome or distressing symptom associated with cancer and 
its treatment (Holley, 2000a). 
Fatigue is a problem for patients undergoing treatment for cancer, with 39% 
reporting significant fatigue over the course of radiotherapy (Prue, Rankin, Allen, 
Gracey, & Cramp, 2006). Given the significance of the problem of Cancer Treatment-
Related Fatigue (CTRF), participants in the National Institutes of Health (NIH) State of 
the Science Conference on Symptom Management for Pain, Depression, and Fatigue in 
Cancer Patients (National Institutes of Health, 2002) identified a need to “develop 
conceptual models to direct systematic research into pain, depression and fatigue alone 
and together that have well-delineated criteria for definition and assessment of their 
interrelationships” (p. 16). 
Cancer Treatment-Related Fatigue 
Although CTRF is a nearly universal side effect of cancer treatment, it has 
received relatively little attention compared to other symptoms in cancer patients 
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(National Institutes of Health State-of-the-Science Panel, et al., 2004). CTRF is defined 
as fatigue that “is a distressing, persistent, subjective sense of physical, emotional and/or 
cognitive tiredness or exhaustion related to cancer or cancer treatment that is not 
proportional to recent activity and interferes with usual functioning” (Berger, et al., 2009, 
pp. FT-1). Fatigue in the context of the proposed study is described as a “subjective, 
multidimensional sensation … best measured by the patient’s self-report” (Piper, 2003, p. 
209) and defined as “a debilitating, unusual sense of tiredness that differs significantly 
from the transient, more easily relieved sense of tiredness … more commonly … 
experienced by healthy individuals” (Piper, 2003, p. 210). CTRF is common with 
reported incidence of 68% in patients undergoing radiation treatment for cancer (Hickok, 
Morrow, Roscoe, Mustian, & Okunieff, 2005). 
The precise contribution of biological factors to the intensity of CTRF has not 
been clearly established. It is likely that multiple physiologic factors (e. g., decreased 
oxygenation due to decreased hemoglobin, endocrine disorders such as hypothyroidism, 
and cachexia caused by substances such as Tumor Necrosis Factor – Alpha (TNF-a), 
Interleukin (IL)-1 and IL-6 and Interferon 12 contribute to the development of fatigue 
(Berger, et al., 2009). Biological researchers have found objective muscular fatigue in 
prostate cancer patients undergoing radiation therapy by conducting tests of voluntary 
skeletal muscle strength and endurance (Stone, Hardy, Huddart, A'Hern, & Richards, 
2000). Evidence suggests that fatigue is associated with anemia, and those patients who 
respond to treatment with erythropoietin resulting in a hemoglobin rise of 2 gm/dl 
experience a significant decrease in fatigue (Berger, et al., 2009; Cella, Kallich, 
McDermott, & Xu, 2004). However, other research has found a correlation between high 
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baseline red blood cell count and fatigue in patients receiving radiotherapy for breast 
cancer (Wratten, et al., 2004). Improvement in fatigue has been seen in patients who 
engage in exercise during treatment for cancer (Berger, et al., 2009; Mock, et al., 1997; 
Mock, et al., 2001; Schwartz, Mori, Gao, Nail, & King, 2001) 
The lack of evidence for definitive biological correlates for CTRF is expected 
given the subjective nature of fatigue. As with other symptoms, patient self-report is the 
most appropriate means of understanding the CTRF experience (Berger, et al., 2009; 
Piper, 2003). Research suggests a relationship between the intensity of CTRF and factors 
such as depressive symptoms, feelings of hopelessness, and pain in patients with cancer 
(Dodd, Miaskowski, & Paul, 2001; Pasacreta, 1997; Ringdal, 1995). In the context of 
cancer treatment, factors such as reaction to the cancer diagnosis, symptom distress, and 
social support have been related to CTRF (Berger & Walker, 2001). Furthermore, CTRF 
remains a problem for cancer patients even after treatment has ended, affecting all 
dimensions of quality of life including psychological and spiritual well-being (Berger, et 
al., 2009; Ferrell, et al., 1996; Longman, Braden, & Mishel, 1996). 
Cancer Treatment-Related Fatigue Distress 
Perhaps the most important component of CTRF is the distress that it causes for 
cancer patients. CTRF distress is defined as suffering or mental anguish specifically 
related to the CTRF experience (Holley, 2000b). CTRF distress is a unidimensional 
construct (Holley, 2000a, 2000b). Research suggests CTRF distress is associated with 
symptom intensity, perceived ability to cope with symptoms, depressive symptoms, and 
disruption in daily life (Pasacreta, 1997; Richardson, Ream, & Wilson-Barnett, 1998; 
Winningham, et al., 1994). CTRF distress has been understudied in comparison to the 
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other components of the CTRF experience, with little attention given to factors 
explaining the development of CTRF distress. However, there is evidence that ability to 
manage CTRF may decrease distress associated with the symptom (Johnson, 1996, 1999; 
Johnson, Fieler, Wlasowicz, Mitchell, & Jones, 1997). In addition, interviews with 
patients suffering from CTRF distress suggest that distress may result from the impact of 
CTRF on the physical, social, emotional, and cognitive aspects of their lives (Holley, 
2000a, 2000b). 
Theoretical Model of the CTRF Symptom Experience 
 The CTRF symptom experience as proposed for this study is grounded in the 
symptom experience literature, which conceptualizes symptoms as consisting of two 
components: symptom occurrence and symptom distress. Symptom occurrence includes 
features of intensity, quality, and duration. In the proposed study, the broad concept of 
CTRF occurrence is labeled as CTRF. The features of CTRF occurrence are labeled 
specifically throughout this proposal as CTRF intensity, quality, or duration. The distress 
component of the CTRF experience is labeled throughout as CTRF distress. 
The model of symptom experience (Rhodes & Watson, 1987) and the Common 
Sense Model of Self-Regulation, (Keller, Ward, & Baumann, 1989; Leventhal & 
Diefenbach, 1991; Leventhal, Halm, Horowitz, Leventhal, & Ozakinci, 2004; Leventhal, 
Meyer, & Nerenz, 1980; Skelton & Croyle, 1991; Ward, 1993) along with empirical and 
theoretical literature related to symptoms (Lenz, Pugh, Milligan, Gift, & Suppe, 1997; 
UCSF School of Nursing Symptom Management Faculty Group, 1994) and CTRF (Nail, 
2002; Nail & King, 1987; Nail & Winningham, 1995) guided the selection of variables 
for model development. 
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The proposed model (Figure 1) postulates that patients’ CTRF Representation mediates 
the development (or absence of) CTRF distress among patients with CTRF. This model 
will be used to test the construct validity of the CTRFRep instrument. 
Assumptions implicit in the model of CTRF presented in Figure 1 include: 1) 
symptom perception involves cognitive, active, constructive organization of bodily 
sensations; 2) abstract, perceptual, and procedural memory systems are involved in 
converting somatic sensations into representations; and 3) specific procedures and ways 
of responding to somatic sensations work to transform symptom perception into 
representations, and ongoing efforts are aimed at reducing the impact of the threat of the 
symptom or illness and its emotional consequences (Leventhal & Leventhal, 1993). 
 As shown in Figure 1, contextual factors are particular constructs that have been 
shown to be associated with the development of CTRF and CTRF distress. 
Figure 1: Proposed model of the Cancer Treatment-Related Fatigue symptom 
experience 
Note: Partial model used to assess the construct validity of the CTRFRep instrument 
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Characteristics such as demographic variables, (e.g., age, race, marital and employment 
status) depressive symptoms, and affect have been found to be associated with symptom 
reporting and/or CTRF intensity and distress (Cameron, Leventhal, & Love, 1998; Mora, 
Robitaille, Leventhal, Swigar, & Leventhal, 2002). CTRF intensity is defined as the 
perceived degree or relative strength of CTRF.  
Cancer Treatment-Related Fatigue Representation 
 The common sense model of illness representation (Leventhal, Brissette, & 
Leventhal, 2003; Leventhal, et al., 2004; Leventhal & Leventhal, 1993) is an 
information-processing model proposing that “individuals are … motivated to construct 
meanings for body sensations in order to engage in self-regulating behaviors” (Keller, et 
al., 1989, p. 55). In the proposed model, it is hypothesized that CTRF representation 
mediates the relationship between CTRF intensity and CTRF distress. 
Representations can be on very concrete (e. g., living with the side effects of 
chemotherapy) and on more abstract levels (e. g., believing that chemotherapy is killing 
cancer cells), which may or may not be congruent with one another (Johnson, 1997). In 
addition, information processing of representations occurs on both cognitive and affective 
levels. CTRF representation is the set of beliefs, thoughts and related emotions cancer 
patient uses to organize, analyze, and interpret information about CTRF (Leventhal & 
Leventhal, 1993). CTRF representation is unique to each person and is based upon the 
individual’s perception and evaluation of the meaning of CTRF. Representations have 
attributes in six categories (Leventhal, et al., 2004). 
•  Identity (e. g., concurrent symptoms that are related to or contribute to the 
CTRF experience); 
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•  Time-line or the pattern of CTRF (e. g., comes and goes, predictable vs. 
unpredictable, always there, improving or worsening);  
•  Consequences of CTRF (e. g., positive or negative short-or long-term 
outcomes of having CTRF); 
•  Causes of CTRF (e. g., the patient’s beliefs about the causes of CTRF); 
•  Controllability or curability of CTRF (e. g., whether CTRF can be improved); 
•  Symptom Coherence (e.g. making sense of the CTRF experience). 
CTRF representations develop over time and are influenced by life experiences, 
including interaction with friends and relatives. For this reason, representational beliefs 
may be somewhat resistant to change and may or may not be objectively accurate 
(Leventhal, et al., 1980). To illustrate, a person with new-onset CTRF may believe that 
sleeping a lot more will improve it. However this behavior is reported to worsen CTRF, 
whereas exercise is reported to improve CTRF in patients undergoing treatment for 
cancer (Mock, et al., 2005). Although representational beliefs can be resistant to change, 
it is hypothesized that they can be influenced by interaction with a health care provider 
and by accurate disease and treatment information (Leventhal, et al., 2004). 
In terms of interacting with health care providers, Bowen (2006) has identified a 
need for health care providers to receive training that helps them develop and elicit from 
patients their stories to develop a problem representation that is accurate and allows them 
to generate a hypothesis about the illness script to arrive at a diagnosis for the patient. 
The development of problem representations and selection of illness scripts have been 
discussed by Fisch (2009) as being the missing pieces in fatigue evaluation for cancer 
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patients. This discussion is very analogous to the developmental process for 
representations in cancer patients presented in Chapter 2. 
To date, there are no reported measures of CTRF representation. The Cancer 
Treatment-Related Fatigue Representation scale (CTRFRep) is designed to capture self-
reported representations of CTRF. The elements of CTRF representation to be included 
are 1) beliefs about the causes and consequences of CTRF, 2) perceptions of identity, 
time-line, and controllability and 3) emotional representations. The proposed study 
involves the development and testing of a crucial link (i.e., a reliable and valid measure 
of CTRF Representation) for use in testing the model of CTRF experience in Figure 1. 
This model can provide the foundation of a program of research to elucidate the 
cognitive/affective and concrete/abstract dimensions of CTRF representation, and the 
relationship of these variables to the development of CTRF distress.  
Appraised Effectiveness of CTRF-managing Strategies 
CTRF representations drive behaviors to decrease or eliminate representations. 
The outcomes of these behaviors are appraised for effectiveness. Appraised effectiveness 
of CTRF-managing strategies is defined as one’s evaluation of the adequacy of CTRF-
managing strategies in terms of the outcome desired from the strategies (e. g., did the 
strategy relieve the CTRF or did the strategy reduce the threatening impact of the 
fatigue?) and the costs of the strategies (e. g., did using the strategy negatively effect 
social, physical, or emotional well-being?) (Leventhal, et al., 2004; Leventhal & 
Leventhal, 1993; Paul, West, Lee, & Miaskowski, 2003). Appraisal of effectiveness is a 
way for the patient to evaluate his or her competency to manage the threat of CTRF 
(Leventhal & Leventhal, 1993). However, because the purpose of this study is to begin to 
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establish the construct validity of the CTRFRep scale, and not to test the model as 
proposed in Figure 1, appraised effectiveness has been bracketed out of the proposed 
study. 
Several studies have investigated the use of self-care strategies for fatigue and 
other symptoms in patients with cancer. Often-used CTRF-managing strategies were: 1) 
activity/rest related strategies such as taking more frequent naps and engaging in light 
physical activity (Berger, Farr, Kuhn, Fischer, & Agrawal, 2007; Berger, et al., 2005; 
Nail, et al., 1991; Richardson & Ream, 1997); 2) psychological strategies such as 
maintaining hope (Seegers, et al., 1998), relaxing (Richardson & Ream, 1997), and 
keeping busy (Nail, et al., 1991); and 3) social interaction strategies such as engaging in 
hobbies and socializing with friends (Graydon, Bubela, Irvine, & Vincent, 1995; 
Richardson & Ream, 1997). As with other research on CTRF, many of these studies 
examined self-care strategies for women undergoing chemotherapy for breast cancer 
(Badger, Braden, & Mishel, 2001; Graydon, et al., 1995; Seegers, et al., 1998). A few 
studies included men in their samples, but these studies were of chemotherapy patients 
(Nail, et al., 1991; Richardson & Ream, 1997). None of the strategies used were 
completely effective in managing CTRF intensity, (Nail, et al., 1991; Richardson & 
Ream, 1997) and CTRF distress was not evaluated as an outcome in these studies. Thus, 
the influence of the strategies themselves – or the perceived effectiveness of the strategies 
on CTRF distress – is not known. 
Cancer Treatment-Related Fatigue Distress 
 CTRF distress, the suffering and mental anguish specifically related to the CTRF 
experience, can be related to physical, psychological, spiritual, social and cognitive 
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difficulties that arise from CTRF intensity (Holley, 2000a, 2000b). Level of CTRF 
distress is the outcome variable in the proposed model. Historically, measures of CTRF 
have primarily focused on CTRF intensity. Recently researchers have begun to recognize 
the need to assess the distress component of the fatigue experience and the factors that 
relate to CTRF distress (Holley, 2000b). Instruments have been developed to measure 
CTRF distress as well as intensity (Rhodes & Watson, 1987). 
Conclusion 
 In summary, current research on fatigue in chronic illnesses has several 
limitations (Paterson, Canam, Joachim, & Thorne, 2003) including: 1) attributing fatigue 
exclusively to disease and isolating it from the context in which it occurs; 2) seeing 
fatigue as being the same for all who have it; and 3) seeing it as necessarily problematic. 
The proposed model of the CTRF experience addresses these limitations by exploring 
CTRF representation as a mental link to fatigue that may have been present prior to 
cancer treatment, and evaluating CTRF in the context of demographic and treatment 
variables, concurrent symptoms, and affective variables. The proposed model also allows 
for consideration of individual differences in representations of fatigue while seeking to 
identify factors that contribute to the development or absence of CTRF distress.  
 However, before the proposed model can be used to test the CTRF experience in 
people with cancer, the CTRFRep scale, a crucial component of model must be validated. 
The model as described in Figure 1 serves to diagram the relationships to be tested when 
evaluating the construct validity of the CTRFRep instrument. Therefore, the purpose of 
this cross-sectional study is to report on the development of a measure of CTRFRep and 
describe its psychometric properties in patients undergoing radiation treatment for cancer. 
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Specific Aims 
1. Identify the factor structure of the CTRFRep scale. 
Research Question 1a: What is the factor structure of the CTRFRep Cause 
subscale? 
Research Question 1b: What is the factor structure of the Timeline, 
Consequences, Control, and Emotional Representation subscales? 
2. Describe the internal consistency reliability of the CTRFRep scale. 
Research Question 2: What is the internal consistency reliability of the CTRFRep 
Identity, Timeline, Consequences, Cause, Control, and Emotional Representation 
subscales? 
3. Describe the construct validity of the CTRFRep scale.  
Hypothesis 3a: The CTRF Identity subscale will show a significant difference 
between the symptoms experience subscale and those associated with CTRF 
(Moss-Morris, et al., 2002). 
Hypothesis 3b: CTRFRep subscales mediate the relationship between CTRF 
intensity and CTRF distress. 
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CHAPTER 2: REVIEW OF THE LITERATURE 
Introduction 
The prior chapter introduced the nature of the proposed study, including the 
problem, purpose, specific aims and research questions, and the conceptual definitions of 
the variables of interest in the study. This chapter provides an overview of chronic illness 
and the common sense model of self-regulation (CSMSR) – the theoretical framework 
that undergirds the present study. The chapter concludes with a review of the literature 
involving the variables of interest in the study.  
Chronic Illness 
 The common sense model of self-regulation (CSMSR) is a framework through 
which chronic illnesses can be understood from the perspective of the patient. The model 
has been refined over the past three decades, (Leventhal, et al., 2004; Leventhal & 
Leventhal, 1993; Leventhal, et al., 1980) including development and refinement of key 
concepts in the model and their relationship to patient outcomes (Leventhal, et al., 2004). 
In order to discuss the CSMSR it is first necessary to understand the biologic 
characteristics of chronic illness. As described by Leventhal et al. (2004), chronic 
illnesses may be characterized as being  
• systematic, affecting multiple body systems and a wide range of physical and 
social functions(Leventhal, et al., 2004, p. 198); 
• diseases or disorders that develop over many years though most become clinically 
visible later in life; 
• controllable but often not curable; 
• often insidious in character impinging gradually on a wide range of life activities; 
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• often noted to have indolent and acute phases, which can be severe and 
unpredictable in nature (p. 198). 
According to Leventhal et al., (2004) chronic illnesses such as cancer can affect 
patients in ways that are similar to non-illness stressors (e. g., divorce, combat service, 
job loss). However, chronic illnesses share several characteristics that distinguish them 
from non-illness stressors. First, chronic illnesses are widespread in the community, and 
are likely to be shared experiences that affect patients for the rest of their lives. Second, 
they affect one’s ability to gather the internal resources (e.g., physical and psychological) 
needed to effectively adapt to the illness (Leventhal, et al., 2004). Third, most “develop 
over years and decades” (Leventhal, et al., 2004, p. 200). Fourth – and particularly in the 
case of cancer – the treatments necessary to control chronic illnesses “may have side 
effects that are seemingly as disruptive of life and physically invasive and life threatening 
as the illness itself” (Leventhal, et al., 2004, p. 201). Fifth, chronic illnesses and their side 
effects can cause lengthy and severe emotional distress. Finally, chronic illnesses occur 
within a cultural and institutional context that presents a complicated set of issues for 
those facing them (Leventhal, et al., 2004). 
Cancer as a Chronic Illness 
In recent years, given the improvements in treatments and concurrent lengthening 
of life after diagnosis with cancer, cancer is increasingly being viewed as a chronic 
illness (Bahls & Fogarty, 2002). According to the American Cancer Society (2008) the 
five-year survival rate for all cancers has increased to 66% in the years 2003-2006 from 
50% in the years 1975-1977. While this is a fortunate situation, living with cancer also 
means living with the short- and long-term side effects of treatment as well as the follow-
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up care that is required to identify relapse and maintain remission. For these reasons, 
cancer can be viewed as a chronic illness for many patients.  
Self-Regulation Models 
There are several benefits of using self-regulation models to study chronic illness. 
First, self-regulation models encourage understanding of chronic illness as greater than 
appraisal of its size as related to coping resources (Leventhal, et al., 2004). Second, this 
type of model is flexible and oriented toward the process. This allows the formation of 
hypotheses that respect the information processing that patients do based on their own 
experiences and activity in order to monitor changes and problem solve over time 
(Leventhal, et al., 2004). Third, these models use a problem-solving approach that speaks 
to the close “relationship between the physiological and biomechanical events that [cause 
symptoms and the beliefs regarding the] targets and procedures for disease management” 
(Leventhal, et al., 2004, p. 208).  
Common Sense Model of Self Regulation (CSMSR) 
The CSMSR is similar to other stress-coping frameworks in that it is formulated 
upon control systems principles in which behavior is in harmony with one’s goals, 
methods of attainment of those goals, and appraisal of the outcome of those methods. 
However, the CSMSR is based upon different assumptions and attempts to integrate key 
concepts from stress-coping frameworks as well as other models to provide a more 
comprehensive model of the experience of having a chronic illness (Leventhal, et al., 
2004).  
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Assumptions 
As stated by Leventhal et al., (2004), the underlying assumptions of the CSMSR 
include: 
1. The individual patient is viewed “as a common-sense ‘scientist’ [e.g., biologist, 
doctor, or psychologist] trying to make sense of her/his world ... [in order to] 
understand and manage [the] chronic-illness experience” (p. 209);  
2. “The adaptive process is based on common sense beliefs and appraisals” 
(Leventhal et al., 2001, p. 20); 
3. The model consists of a hierarchical structure including the problem space (e.g. 
the experience of chronic illness) within the context of the self and the self 
within the socio-cultural perspective. 
This process results in a dynamic interpretation of illness experiences with 
engagement of any number of methods of management. Within the problem space exist 
illness representations, which include the illness label and symptoms as well as an 
“elaborate set of meanings that defines the problem … for self-management” (Leventhal, 
et al., 2004, p. 210). Expanding upon these assumptions, viewing the patient as a 
common sense scientist (assumption 1) allows for identification of multiple procedures or 
rules of thumb for the construction of representations of illness threats (Leventhal, et al., 
2004). 
Concepts 
The major concepts within the CSMSR include the somatic stimulus (e.g., cancer 
or fatigue) and the meanings attached to them; representation, or the beliefs thoughts and 
emotions surrounding the experience of illness and its treatment; coping procedures used 
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to manage illness and side-effects of treatment; action plans for the coping procedures 
and the outcome appraisals of the effectiveness of the coping procedures.  
The somatic stimuli for this study include cancer, its treatment, and CTRF. The 
heuristics are those things from the patient’s history or knowledge base that lead to an 
interpretation of the event, an example of a heuristic is symmetry – matching symptoms 
to labels. 
Hierarchical Structure 
 The CSMSR assumes a nested hierarchical structure (see Figure 2), which 
includes the problem space, the self-structure, and the socio-cultural and ecological 
context. The fundamental level – or the problem space – includes the disease label, its 
signs and symptoms, and the procedures used for managing and coping with them 
(Leventhal, et al., 2004). Over time, continuing interpretation of symptoms and appraisal 
of the efficacy of specific procedures for dealing with these symptoms create an ever 
more complex representation. According to Leventhal et al., (2004) “a central proposition 
of the [CSMSR] is that patients regulate experiences, symptoms, and functional changes 
over time. This functional level, the ‘problem space,’ is at the heart of the self-regulation 
process” (p. 209). 
Social, cultural and ecological context 
Self-structure 
Problem Space 
Figure 2: Nested hierarchical structure of the CSMSR 
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Within the nested hierarchy, the problem space is contained within the structure 
of the self. The self-system is further nested in the context of society, culture and ecology 
(Leventhal, et al., 2004), which integrates many concepts recognizable from bio-
behavioral research. These concepts include perceived control, self-efficacy regarding 
illness and symptom management (Bandura, 1977), and self-assessed health.  
Self-management in the problem space 
Illness representations. 
Illness representations (see Figure 3) consist of the beliefs, thoughts, and 
emotions surrounding the experience of having an illness and are characterized by beliefs 
about the identity, time-lines, consequences, causes, controllability, and the emotional 
response to having an illness. According to Leventhal et al., (2004) representations of 
chronic illness contain five cognitive factors which vary both among illnesses and within 
the individual’s experience of having a chronic illness: 1) illness identity or the “names or 
labels which carry expectations about how they will impact life” [… these include the …] 
“experienced symptoms, signs and changes in function” (p. 210). The names or labels 
and the actual experience of the illness combine to describe illness identity; 2) control, 
both actual and perceived control of chronic illness; 3) time-lines involved with both 
chronic illness and its treatment; 4) illnesses are seen as having multifaceted causes, and 
beliefs about these causes can vary based on an individual’s age and past experience; 5) 
chronic illness presents a “set of expected and perceived consequences with respect to its 
physical impact and how these physical changes will affect daily function” (Leventhal, et 
al., 2004, p. 210). Because representational beliefs develop in both the cognitive and 
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affective domains, there is also a component of emotional representation, which 
represents the thoughts and emotions surrounding the illness experience. 
Each of the factors within illness representation can also apply to treatments and 
symptoms (Horne, 2003; Leventhal, et al., 2004). Thus, a patient’s experience of cancer 
includes representational beliefs about the cancer, its treatment(s) and side effects, and 
symptoms such as fatigue or pain, which can be the result of cancer or of its treatment.  
Multilevel Structure. 
According to Leventhal et al., (2004) within the five cognitive domains of 
representation, factors are represented at two levels, experiential (or concrete) and 
abstract. Concrete experiences are symptoms, signs, or functional difficulties that often  
lead to the realization of a problem, for example through the experience of fear or anxiety 
(Martin, Lemos, & Leventhal, 2001). Abstract phenomena include the symptom or illness 
label, and clock or calendar time (Leventhal, et al., 2004). It is through the connection of 
the concrete and abstract experiences, for example the symptom labeled headache felt 
over the course of days or weeks that may prompt one to seek identification of an illness 
Figure 3: Contents of illness, treatment, and symptom representations 
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label, that depth is given to the representation. Patients must recognize a significant 
disturbance to their daily lives or a significant change in their functional abilities in order 
to seek out care (Scheier & Carver, 2003). 
When the abstract notions of time and label are applied to concrete (experienced) 
symptoms such as fatigue and pain in patients with cancer, different people will react in 
different ways. Depending on one’s interpretation of the symptoms, the individual with 
cancer may believe that these symptoms are cues to the ‘common’ side effects of 
treatment or the worsening of the cancer itself. In the absence of illness representations 
including both concrete and abstract levels, patients may not realize the significance of 
the symptoms in the context of cancer and its treatment (Leventhal, et al., 2004). 
Heuristics. 
Heuristic is defined as “of or relating to exploratory problem-solving techniques 
that utilize self-educating techniques … to improve performance” (2002). More casually, 
heuristics are “rules of thumb” (Heuristic, 2009) patients develop based on their prior 
experience or knowledge and use to make sense of their experience with chronic illnesses 
such as cancer. One common heuristic is the “age-illness heuristic” which involves 
beliefs or attribution of signs and symptoms to aging rather than to an illness. Another 
heuristic is the “stress-illness” heuristic in which attributions are made to stress rather 
than illness. According to Leventhal et al., (2004) other heuristics include: 
• locational, where symptoms are attributed to the location of the effect versus the 
location causing the symptom [e.g. dyspnea and foot swelling (location of effect) 
because of heart failure (location of the cause)]. 
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• prevalence, in which symptoms or signs are graded as less severe if an individual 
sees that not only oneself but numerous others are at risk of contracting a certain 
disease. 
• affective, in which individuals with depressed mood or anxiety may view 
themselves as more vulnerable to illness, or more likely to be ill than those with 
euthymia. 
• duration, in which symptoms of longer duration are viewed as more threatening 
than symptoms of brief duration. 
An example of a rule of thumb regarding cancer treatment-related fatigue is the 
idea that fatigue will improve if he/she rests more. Based on prior experiences with 
severe tiredness from other severely tiring illnesses such as a bout of the flu, the patient 
develops the belief that resting more will help the cancer treatment-related fatigue. 
However, in the case of CTRF too much rest can lead to deconditioning, which can 
increase levels of fatigue (Barsevick, Newhall, & Brown, 2008). In addition, patients may 
believe that a ‘good day,’ when their fatigue level is relatively low, is an ideal time to put 
in a full day at work or fulfill other obligations. When the patient’s problem is CTRF, 
however, working a full day or overexerting oneself may result in extreme fatigue with a 
prolonged recovery period relative to the amount of exertion normally felt before cancer 
and its treatment.  
Temporal change: dynamics. 
Symptom and illness representations are formed and remodeled “by changes in 
the disease process, by feedback from professional care and self-care, and by social 
information” (Leventhal, et al., 2004, p. 212). Patients can learn about the experience of 
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cancer treatment and its side effects from multiple sources such as family members, 
observation of, and comparison to other cancer patients, and reports in the popular media. 
Personal experience over time will interact with ongoing self-appraisal heuristics and 
become a key component in efforts to understand concrete illness and symptom 
experiences (Leventhal, et al., 2004) 
Procedures for self-regulation 
The CSMSR suggests that the intensity and length of signs and symptoms, along 
with the implications and understanding of them, will affect the selection of procedures 
for management, and that the selection of a procedure is infrequently random. The 
CSMSR recognizes a variety of particular procedures that may be chosen by an 
individual with chronic illness (Leventhal, et al., 2004). These actions include traditional 
and complementary or alternative medicine, herbal supplements, and modifying lifestyle 
activities. Procedures may be selected for a variety of reasons, such as control of signs, 
symptoms, functional abilities, or emotions, or a mix of these events, and these 
procedures may or may not be believed to be usefully controlling the disease itself 
(Leventhal, et al., 2004). 
Illness representations and choice of procedures 
Patients with cancer treatment-related fatigue may have symptom representations 
that affect their perception of fatigue and its associated distress. Anecdotal evidence 
suggests that patients who received chemotherapy treatment for recurrent Non-Hodgkin’s 
Lymphoma had lower levels of fatigue distress than patients who received first-time 
chemotherapy treatment for primary Hodgkin’s Lymphoma, even though the level of 
fatigue intensity was similar in both groups (Reuille, 2002). 
 22 
 
Treatment and symptom representations 
The five domains of illness representation are also seen in treatment 
representation. “Beliefs about [treatment] identities (symptoms), time-lines for efficacy, 
consequences (side effects), and causal mode of action” apply to the evaluation and 
choice of treatments (Leventhal, et al., 2004, p. 213). Thus, “there is more to the 
evaluation and selection of a treatment than the perception of its … effectiveness … [or 
its potential] for curing and/or controlling disease” (Leventhal, et al., 2004, p. 213). 
An example of an illness with complex treatment representations is prostate 
cancer. Surgical options connote ‘getting rid’ of the cancer but involve surgery that has 
possible side effects of incontinence and impotence, whereas radiation treatment may be 
as effective as surgery, but has its own side effects and negative stigma. Selecting no 
treatment at all (i.e. watchful waiting) is also an option, which can be fraught with side 
effects such as increased anxiety (Allaf & Carter, 2004)  
Action plans 
Patients “may be motivated to act, that is perceive a treatment or self-care 
behavior as necessary, have specific goals (symptom control), and specific coping 
procedures in mind, yet fail to act if they have not formed an action plan” (Leventhal, et 
al., 2004, p. 214). Strategic action planning may be of benefit either by minimizing 
memory burden and “the need for conscious retrieval by shifting the control of behavior 
from internal thoughts and intentions to stable external cues, or because they promote 
rehearsal of the behavior and generate commitments to action” (Leventhal, et al., 2004, p. 
214). 
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Performance and performance appraisals 
According to Leventhal et al., (2004) individuals often assess the efficacy of 
treatment for chronic illness based on the performance of the treatment in controlling the 
condition. However, feedback can be quite ambiguous for many chronic conditions and 
the feedback that is recognized may be negatively valenced. Often the individual is not 
sure if the treatment is working or not, and the evidence that it is working (e.g. alopecia 
from chemotherapy) can be distressing (Boehmke & Dickerson, 2005). “The target of self 
management, for example the chronic disease versus its symptoms can have important 
consequences both for the appraisal of control efforts and for emotional 
adjustment”(Leventhal, et al., 2004, p. 215). Patients may experience higher levels of 
emotional distress if they focus on curing what may be an incurable condition (i.e. 
cancer). On the other hand, less distress may be felt when efforts are focused on 
managing symptoms (e. g., fatigue) (Leventhal, et al., 2004). 
Coherence in the problem space 
According to Leventhal et al., (2004) when feedback reveals patients are 
successful in moving toward goal attainment while using self- or medically-based 
treatments, (i.e. “goals established by the illness representation are being met” (pp. 215-
216)) the problem solving process (the problem space) is coherent. Coherence allows for 
behavioral consistency, until there is inconsistent feedback, but it does not assure 
constructive health results. “Coherence is at the heart of expertise in self regulation” 
(Leventhal et al., p. 216).  
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CTRF Experience Model (Figure 1) Variables 
The model of the CTRF experience contains the variables presented in Figure 1 in 
the previous chapter. Below is a review of the literature for the major variables within 
this model as they are used for hypothesis testing in the present study. 
Depressive Symptoms 
 Depressive symptoms are defined as having components of depressed mood and 
feelings of guilt or unworthiness, and hopeless or helplessness, as well as problems with 
eating, sleeping, and psychomotor retardation (Radloff, 1977). Depressive symptoms 
have been found to be correlated with fatigue in patients with cancer. 
In a cross-sectional study of 109 women receiving adjuvant treatment (40 percent 
chemotherapy; 10 percent RT; 39 percent both chemo and RT) or surveillance for breast 
cancer, Bennett, Goldstein, Lloyd, Davenport, and Hickie (2004) found that 20 percent of 
patients reported significant levels of both fatigue (as measured by the Functional 
Assessment of Cancer Therapy fatigue (FACT-F) and psychological distress as measured 
by the SOMA-6). Seventeen percent reported only fatigue and ten percent reported only 
psychological distress, while 52 percent of women reported no symptoms (Bennett, et al., 
2004).  
In a mixed sample of 1129 patients undergoing radiation therapy for cancer, 
Hickok et al., (2005) found that nearly 50 percent of patients reported ‘feeling upset’ as 
rated on a 0-10 scale on a symptom inventory at the beginning of radiation therapy, with 
nearly 20 percent expressing moderate (rating of 4-6) or severe (rating of 7-10) problems 
with ‘feeling upset’ at baseline. Among 419 patients for whom longitudinal data was 
available, problems with ‘feeling upset’ remained relatively stable over time, with 
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slightly over 30 percent reporting worsening of the symptom, and slightly under 30 
percent reporting improvement in the symptom at week 5 as compared with their baseline 
levels (Hickok, et al., 2005). 
In a cross-sectional controlled comparison study of 227 persons with various 
cancers and 98 controls, Stone, Richards, A'Hern, & Hardy (2000) defined severe fatigue 
as being a level that was at the 95th percentile of the control group. This study found that 
the prevalence of severe fatigue in patients with cancer was 48% overall and ranged from 
15% in women with breast cancer to 78% in persons with advanced cancer. The results of 
this study showed that depression as measured by the Hospital Anxiety and Depression 
(HADD-8) subscale was significantly correlated (r = 0.60) with fatigue (as measured by 
the Fatigue Severity Scale) and that after dyspnea, depression accounted for 14% of the 
variance in fatigue.  
In a study of 105 patients newly diagnosed and treated for prostate cancer 
Monahan et al, (2007) found that depressive symptoms at four weeks post-treatment (as 
measured by the CES-D) significantly predicted vitality at one year post-treatment (as 
measured by the MOS SF-36 vitality subscale) after controlling for demographic and 
treatment information. Those with lower depressive symptoms at 4 weeks had 
significantly higher vitality scores at one year.  
 The above studies suggest that depressive symptoms are related to fatigue 
intensity in patients with cancer. A limitation of the current research in this area is that a 
wide variety of instruments were used to measure both depressive symptoms and fatigue. 
However, the consistent findings of a relationship between fatigue intensity and 
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depressive symptoms suggest that depressive symptoms may be useful in testing the 
construct validity of the CTRFRep. 
Negative affect and symptom reporting 
 Negative affect is defined as a state of being in which people express a “general 
dimension of subjective distress and unpleasurable engagement that subsumes a variety 
of averse mood states … [e.g.,] anger, … guilt,… fear, and nervousness” (Watson, Clark, 
& Tellegen, 1988, p. 1063). By contrast, people expressing low levels of negative affect 
express “a state of calmness and serenity” (Watson, et al., 1988, p. 1063). Studies suggest 
a correlation between negative affect and symptom reporting, in which patients with 
higher levels of negative affect report more symptoms (Mora, et al., 2002). However, few 
studies have evaluated this relationship in patients with cancer.  
In a study of 114 in- and out-patient surgical cancer patients, Koller, Heitmann, 
Kussmann, and Lorenz (1999) found a strong positive correlation (r=0.72; p<0.01) 
between somatic symptom reports as measured by the European Organization for 
Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-C30 
version 2.0 and negative affect as measured by the EORTC QLQ emotional functioning 
subscale. In a study of 105 patients with advanced cancer Voogt et al. (2005), found that 
negative affect was strongly correlated with anxiety (r=0.72; p<0.001) and depression 
(r=0.48; p<0.001) as measured by the Hospital Anxiety and Depression Scale (HADS). 
Negative affect was also significantly correlated with higher levels of fatigue (r=0.22; 
p=0.02), and pain (r=0.20; p=0.04) as measured by the EORTC QLQ C30 quality of life 
scale. Patients participating in this study were at least six months post diagnosis of their 
advanced cancer. 
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In a longitudinal study of 72 breast cancer survivors in their first 18 months post 
treatment, Kernan and Lepore (2009) examined searching for meaning from their 
experience. A higher level of searching for meaning was correlated with a higher level of 
negative affect. This research suggests that continued searching for meaning may be 
distressing for women with breast cancer (Kernan & Lepore, 2009). Searching for 
meaning is a concept that is somewhat similar to the concept of coherence in CTRF 
representation, in which patients attempt to “make sense of” their CTRF. 
The above studies suggest a relationship between negative affect and symptom 
reporting, including fatigue symptom reporting, in patients with cancer. There is also 
evidence that negative affect may be related to key constructs within the CTRFRep. 
These studies support the notion that negative affect may be an important concept in 
relation to fatigue intensity and CTRF concepts and may be useful in testing the construct 
validity of the CTRFRep.  
Fatigue incidence and severity 
 Fatigue has been identified as a problem for patients who receive radiation 
therapy (RT) treatment for cancer. Radiation therapy is defined as “The use of high-
energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill 
cancer cells and shrink tumors” (National Cancer Institute, 2009). In a study of 208 
patients undergoing RT for various types of cancer, Strauss et al. (2007) found that 
patients experienced significant levels of fatigue (as measured by the Multidimensional 
Fatigue Inventory (MFI-20)) both before and after RT treatment for cancer. Levels of 
fatigue were higher in palliatively vs. curatively treated patients; in those reporting more 
symptoms; and in those with lower Karnofsky Performance Status (Strauss, et al., 2007). 
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One research group examined fatigue in patients undergoing radiation therapy 
(Stone, Richards, A'Hern, & Hardy, 2001) and hormone therapy (Stone, Hardy, et al., 
2000). The study of radiation therapy patients (N=62) included patients with breast and 
prostate cancers (Stone, et al., 2001), and all of the patients with prostate cancer had 
received neo-adjuvant hormone therapy. In the combined sample 69% of patients 
reported that their fatigue worsened over the course of treatment, and 28% reported 
severe fatigue after treatment (Stone, et al., 2001). In a study of 36 veterans undergoing 
radiation therapy for prostate cancer, Monga, Kerrigan, Thornby, and Monga (1999) 
controlled for the presence of co-morbid conditions (e. g., previous myocardial infarction, 
insulin-dependent diabetes, history of depression), and found a significant increase in 
CTRF during treatment (Monga, et al., 1999).  
Several studies of prostate cancer quality of life (QOL) outcomes have included 
measures of fatigue. In a study that examined long-term morbidity of radiation (N=154) 
or surgical (N=108) treatment for prostate cancer, fatigue was found to be significantly 
correlated with overall QOL and, along with emotional and physical functioning, was an 
independent predictor of QOL one year after treatment (Lilleby, Fossa, Waehre, & Olsen, 
1999). 
In a study of patients undergoing neo-adjuvant or primary hormone therapy for 
prostate cancer (N=62), median fatigue scores increased significantly during treatment, 
and 66% of patients reported an increase in fatigue during therapy. In addition, fatigue 
was significantly correlated with psychological distress at baseline (Stone, Hardy, et al., 
2000). In a QOL study of 144 men with asymptomatic prostate cancer, those who 
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underwent hormone treatment (N=79) reported significantly higher fatigue scores than 
those who elected observation (Herr & O'Sullivan, 2000).  
In a study of 353 women within one year of diagnosis for breast cancer, Reuter et 
al., (2006) found a mild to moderate level of fatigue as measured by the Profile of Mood 
States (Mean=9.8, SD=6.8, Range=0-28) among these women. Although 94% of the 
women had received post-surgical treatment of their cancer, the percentages receiving RT 
alone vs. chemotherapy alone vs. RT and chemotherapy were not made clear. 
 In a prospective study of 52 breast cancer patients receiving RT, Wratten et al., 
(2004) identified 43% had significant fatigue throughout treatment as measured by the 
Functional Assessment of Cancer Therapy fatigue (FACT-F) subscale, with the nadir 
occurring during the fifth week of treatment. Fifty-four percent of patients experienced 
minimal fatigue throughout treatment. Those patients who had significant fatigue had 
more fatigue at baseline and had higher counts of neutrophils and red blood cells at 
baseline.  
In a study of 82 men receiving RT for prostate cancer, Miaskowski et al. (2008) 
found that men experienced mild to moderate fatigue with increasing fatigue during 
treatment. Fatigue levels returned to baseline by 25 weeks after treatment (Miaskowski, 
et al., 2008). 
In a study of 1129 patients undergoing RT for various types of cancer, Hickok et 
al., (2005) found that over 60 percent of patients reported fatigue at baseline, and that just 
under half of those patients experienced moderate to severe fatigue. In a sub-sample 
analysis of 419 patients who provided longitudinal data Hickok et al., (2005) also found 
that fatigue severity increased over the course of five weeks of treatment, with 
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approximately 45 percent of patients reporting increased fatigue during treatment, 
whereas approximately 20 percent reported that their fatigue decreased in severity. 
 In a study of 221 patients receiving chemotherapy plus RT (N=100) or RT alone 
(N=121) and age-matched controls without cancer Jacobsen et al., (2007) found that 
breast cancer patients reported significantly more days with fatigue in the past week than 
healthy controls, and that significantly more of the women with breast cancer reported 
abnormal levels of fatigue as measured by the Fatigue Symptom Inventory (FSI).  
 The above studies suggest that fatigue is indeed a problem for patients with 
cancer. The information contained within these studies and others contributes to the 
knowledge base of the fatigue experience in patients with cancer. However, these studies 
also reflect the limitations in the current knowledge base with regard to illness and 
symptom representation.  
Cancer Treatment-Related Fatigue Distress 
Cancer treatment-related fatigue distress is defined as the suffering or mental 
anguish specifically related to the cancer treatment-related fatigue experience. It has been 
relatively understudied when compared to fatigue intensity and severity. Holley (2000a, 
2000b) used qualitative techniques to develop an instrument to measure cancer related 
fatigue distress (CRFDS). The CRFDS was the result of interviews of 17 cancer patients 
and identified distress in the physical, social, spiritual, psychological, and self-care 
domains. The body of work in fatigue distress in patients with cancer is very limited in 
terms of distress when defined as the suffering or mental anguish specifically related to 
the experience of having cancer treatment-related fatigue.  
 31 
 
Other studies have focused primarily on symptom distress as a concept distinct 
from fatigue distress. For example, Leak, Hu, & King, (2008) conducted a descriptive 
correlational study of 30 African-American breast cancer survivors who were at least one 
year post treatment. Twenty-three per cent of the women had moderate symptom distress, 
and there was a significant correlation between symptom distress and poorer quality of 
life. However the Symptom Distress Scale used to measure distress had the anchors of 
1=“normal or no distress” to 5=“experiencing the symptom almost constantly,” which 
appears to mix symptom intensity with symptom distress (Leak, et al., 2008). 
Measurement of Illness and Symptom Representations 
The development of instruments to assess illness representation has been ongoing 
for the past several years. One of the more prominent of these efforts has been the 
development of the Illness Perception Questionnaire-Revised, which has been translated 
into several languages and has seen the development of instruments to measure the illness 
representation of several illnesses (2009). These instruments are notable for their 
psychometric trueness (Moss-Morris, et al., 2002) to the Common Sense Model of Self 
Regulation.  
Measures of symptom representations are being developed by nurse researchers, 
but their development has lagged behind that of illness representations. One instrument, 
the Symptom Representation Questionnaire (SRQ) was recently developed by Donovan, 
Ward, Sherwood, & Serlin (2008). This instrument is based in the CSMSR and was 
derived from the IPQ-R. In these ways, it is very similar to the CTRFRep. It was tested 
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by mailed survey to 713 members of the National Ovarian Cancer Coalition. It is 
a multi-symptom questionnaire and appears to have good psychometric properties 
although it is not as theoretically robust as the IPQ-R (The Identity, Consequence, and 
Emotional Representation items loaded onto a single factor). However, its scope and 
focus is different from that of the CTRFRep, which attempts to capture information about 
Table 1 
Conceptual Definitions of the Concepts Embedded in CTRF Representation 
Term Definition 
CTRF Representation The set of beliefs, thoughts and related emotions through 
which the cancer patient organizes, analyzes and interprets 
information about CTRF 
Identity Symptoms or labels used to define the CTRF experience. 
Time-line Beliefs, thoughts, or related emotions about the acute, 
chronic, and/or cyclical nature of CTRF 
Consequences Beliefs, thoughts, or related emotions about the positive or 
negative long- or short-term outcomes of having CTRF 
Symptom Coherence Beliefs, thoughts, or related emotions about the ability to 
“make sense of” having CTRF 
Cause Beliefs, thoughts, or related emotions about the causes of 
CTRF, including perceived internal, external, and 
behavioral causes 
Emotional Representation Emotional reactions to the threat or danger of having 
CTRF 
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a single symptom that is troubling for cancer patients. A valid and reliable measure of 
CTRF representation can serve a complementary role to instruments such as the SRQ. 
Cancer Treatment Related Fatigue Representation 
To date, there is no measure of CTRFRep. The instrument being tested was 
developed based on the Illness Perception Questionnaire-Revised (Moss-Morris, et al., 
2002). The instrument as being tested appears in Appendix A. Further explanation of the 
instrument and the methods of its development and testing are available in Chapter 3. 
Table 1 provides an overview of the conceptual definitions embedded in the development 
of the instrument. 
Conclusion 
 Cancer is a chronic illness that affects millions of people every year. The 
Common Sense Model of Self-Regulation is a theoretical model that has been useful in 
examining chronic illnesses, as well as their symptoms and treatments. The concept of 
representation can be applied to problematic symptoms such as Cancer Treatment-
Related Fatigue in order to guide the development of knowledge about how beliefs, 
thoughts, and emotions surrounding the experience of CTRF affect patients. A reliable 
and valid measure of CTRF representation is a crucial missing link in a theoretical model 
of the experience of CTRF.  
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CHAPTER 3: METHODS 
Introduction 
This chapter provides information describing the development CTRFRep and its 
content validity testing. The study design, procedures for data collection and protection of 
human subjects are presented. Operational definitions are presented for all study 
variables, and the reliability and validity of study instruments are presented. Finally the 
specific aims, research questions, and hypotheses are presented with plans for data 
analysis. 
Scale development 
The development of the CTRFRep (see Appendix A) relied on adaptation of an 
existing measure of illness perception (The Illness Perception Questionnaire-Revised, 
(IPQ-R), see Appendix B) (Moss-Morris, et al., 2002). The IPQ-R consists of three 
sections; the Identity and Cause subscales are separate from the remaining subscales 
(Moss-Morris et al., 2002). The items in the IPQ-R were adapted to reflect the experience 
of Cancer Treatment-Related Fatigue (e.g., I expect to have CTRF for the rest of my life). 
Additional items were generated from research reports on the experience of Cancer 
Treatment-Related Fatigue. For example, items were added to the Cause subscale to 
reflect treatments for cancer (i.e. radiation and chemotherapy) as possible causes for 
CTRF. In the Identity subscale, several items were added, such as difficulty falling 
asleep, difficulty staying asleep, and difficulty waking up. Table 2 provides a summary of 
the changes made to the Identity and Cause subscales of the CTRFRep, while Table 3 
presents the changes made to the other subscales of the CTRFRep. See Table 4 for 
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information about the items in the subscales of the IPQ-R and the CTRFRep, as well as 
information about the internal consistency reliability of the IPQ-R subscales. 
Methods for Content Validity 
According to Nunnally and Bernstein (1994) there are “two major standards for 
ensuring content validity: 1) a representative collection of items and 2) sensible methods 
of test construction” (p. 102). Each expert was provided with a draft copy of the 
instrument as well as a content validity survey. The content validity survey included the  
conceptual definitions of each of the CTRFRep constructs as they were developed at the 
time (see Appendix C). For the Identity subscale, raters were asked to rate the 
representativeness of the items on a 1-4 scale where 1=not representative and 
4=representative. They were also asked to rate the uniqueness of individual items by 
choosing yes or no, and were asked to cross out items that they would identify as 
redundant. Finally, raters were asked to assess the completeness of the list of symptoms 
in the identity subscale and invited to add their own suggestions for additional items. 
Based on the suggestion of reviewers, nine items were added to the Identity subscale. 
For each of the other subscales (Timeline, Consequences, Controllability, 
Symptom Coherence and Emotional Representation), raters were asked to judge the 
representativeness, uniqueness and clarity (on a 1-4 scale where 1=not at all clear and 
4=completely clear) of the items in the subscale, and to rate whether each set of items 
captured the entirety of the subscale component being evaluated. Generally, the reviewers 
rated the subscales as being complete.  
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Table 2.  
 
Summary of Differences between the IPQ-R and the CTRFRep Identity and Cause  
 
Subscales 
 
Identity Subscale – Items deleted from the CTRFRep 
 Sore throat* 
 Fatigue* 
 Sore eyes* 
 Sleep difficulties* 
Identity Subscale – Items added to the CTRFRep 
 Difficulty falling asleep* 
 Difficulty staying asleep* 
 Difficulty waking up* 
 Muscle soreness* 
 Loss of appetite* 
 Poor concentration* 
 Short attention span* 
 Muscle weakness** 
 Sadness** 
 Lack of energy** 
 Difficulty moving** 
 Low endurance** 
 Numbness or tingling sensations** 
 Feeling blue** 
 No desire to move** 
 Heavy limbs** 
Cause Subscale – Items added to the CTRFRep 
 Having cancer* 
 My radiation treatment for cancer* 
 My surgical treatment for cancer* 
 My hormone treatment for cancer* 
 My chemotherapy treatment for cancer* 
 
*Revision made by investigator 
**Revision suggested by content expert(s) and added by the investigator 
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Table 3. 
 
Summary of Differences between the IPQ-R and CTRFRep Subscales 
 
Items removed from the CTRFRep 
 My treatment will be effective in curing my illness* 
 My treatment can control my illness* 
Items revised 
 There is very little that can be done to improve my illness 
  Revision: Nothing can be done to improve my illness** 
Items added to the CTRFRep 
 I believe medication can help my CTRF get better* 
 I believe that eating a healthy diet will help my CTRF* 
 I know why I have CTRF** 
 My CTRF makes me feel sad** 
 What I do has no effect on my CTRF* 
 If I could sleep more, my CTRF would get better* 
 I take naps during the day for my CTRF** 
 I make sure I sleep at least 8 hours every night* 
 My doctor knows that I have CTRF* 
 Eating well-balanced meals helps my CTRF* 
 I ignore my CTRF as much as I can* 
 I wish my CTRF would just go away* 
 I asked my doctor if there are any medicines or treatments for my CTRF* 
 There are things I can do to make my CTRF better* 
 There is nothing I can do to make my CTRF better* 
 I have asked others (family, friends) for help with my CTRF* 
 Having CTRF helps me realize what is really important in my life* 
 My CTRF helps me spend more time with my family* 
 I can “take it easy” because I have CTRF* 
 All things considered, some good things have come from having CTRF* 
 
*Revision made by investigator 
**Revision suggested by content expert(s) and added by the investigator 
  
 38 
 
Table 4. 
IPQ-R Subscale Internal Consistency Reliabilities and Comparison of IPQ-R Subscale 
Item N with the CTRFRep Subscale Item N 
IPQ-R/ 
CTRFRep subscale 
IPQ-R 
Item N 
IPQ-R 
Alpha 
CTRFRep 
Item N Response Choice 
Identity 12 N/A 26 Yes or No* 
Cause 18 N/A 23 
5 Point Likert Type 
Scale: Strongly 
Agree to Strongly 
Disagree** 
Timeline Acute vs. Chronic 6 0.89 6 
5 Point Likert Type 
Scale: Strongly 
Agree to Strongly 
Disagree** 
Timeline Cyclical 4 0.79 4 
Consequences 6 0.84 6 
Personal Control 6 0.81 16 
Treatment Control 5 0.87 7 
Symptom Coherence 5 0.87 6 
Emotional Representation 6 0.88 7 
Positive Consequences N/A*** N/A 4 
*Endorsement of a) symptom experienced since having CTRF and b) symptom is related to or contributes to 
CTRF 
** For testing purposes, the Likert-type items allow a “does not apply to me” option. 
***Items developed for CTRFRep, not included in IPQ-R 
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Psychometric evaluation of the content validity surveys involved calculation of 
inter-rater agreement and content validity. The content validity index for each subscale 
was calculated from the coding the frequencies of the representativeness data (4=1.0, 
3=0.75, 2=0.50, and 1=0.25), summing these frequencies, dividing by the number of 
content experts (N=4) and dividing by the number of items in the scale. Inter-rater 
agreement was calculated using a similar method, but taking into account the missing 
data in some of the responses, therefore the N for the number of content experts was less 
than four for some of the items. There was no pattern to the missing data within the 
content analysis questionnaires. The inter-rater agreement and content validity indices are 
shown in Table 5. 
Based on the input of the content experts, the scale was evaluated for item 
retention and item addition. The face validity of the items was taken into account. In 
addition, for this initial test of the instrument, items appearing in the original IPQ-R were 
retained in order to facilitate comparison between the psychometric properties of the IPQ-
R and the CTRFRep. Twelve items with a content validity index of less than 0.70 were 
evaluated for editing or deletion. Four of these items were edited prior to inclusion in the 
instrument. These items and the eight additional items will be evaluated for deletion from 
the scale after testing. In addition, items rated as redundant are being retained in the 
instrument during testing and will be evaluated for deletion from the scale after testing.  
As seen in Table 5, both the Control and Identity subscales have inter-rater 
agreement of less than 0.70. In the case of the Identity subscale as published in the IPQ-
R, it contains multiple independent symptoms that may or may not be related to CTRF. 
Although there was some disagreement among the content validity experts about the 
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Table 5. 
Content Validity Index and Inter-Rater Agreement of CTRFRep Items 
CTRFRep Subscale in Content Validity 
Questionnaire Item N 
Inter-rater 
Agreement 
Content 
Validity Index 
Cause 23 .96 .99 
Symptom Coherence 5 1.0 .90 
Consequences  11 .82 .93 
Control (Personal and Treatment) 20 .60 .85 
Emotional Representation 8 1.00 .94 
Identity 17 .40 .78 
Timeline (Acute vs. Chronic and Cyclical) 10 1.00 1.0 
Total Scale 94 .78 .91 
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applicability of the some of the symptoms to the CTRF experience, all symptoms listed in 
the IPQ-R were retained in the instrument as tested to allow for comparison to the factors 
found in the original IPQ-R (Moss-Morris, et al., 2002). Criteria for deletion from the 
final scale will include 1) lack of face validity in the experience of CTRF, 2) item did not 
load on any factor or loaded on multiple factors, and 3) item not endorsed by at least 10% 
of the sample. In terms of the Control subscale, there are two possible reasons for low 
inter-rater agreement. First, this subscale contains the largest number of items added by 
the author. Second, the content validity experts were asked to evaluate the Personal and 
Treatment Control subscales together, and the heterogeneity of the items may contribute 
to lower inter-rater agreement. Several additional items for the Control subscale were 
suggested by the content validity experts. Sample items from the various CTRFRep 
subscales are presented in Table 6. 
Design and methods for psychometric testing 
The purpose of this cross-sectional study is to describe the psychometric 
properties of the CTRFRep instrument in patients undergoing radiation treatment for 
cancer. 
Specific Aims 
1. Identify the factor structure of the CTRFRep scale. 
Research Question 1a: What is the factor structure of the CTRFRep Cause 
subscale? 
Research Question 1b: What is the factor structure of the Timeline, 
Consequences, Control, and Emotional Representation subscales? 
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Table 6 
Sample CTRFRep Subscale Items 
Subscale Item Examples 
Cause: “Stress or worry” “Having cancer” “My emotional state” 
“My radiation treatment for cancer” 
Symptom 
Coherence: 
“My CTRF is puzzling to me” “I have a clear picture or 
understanding of my CTRF” 
Consequences: “My CTRF has major consequences on my life” “Having 
CTRF helps me realize what is really important in my life” 
Control (Personal 
and Treatment): 
“I can do a lot to control my CTRF” “What I do will 
determine whether my CTRF gets better or worse” “There is 
nothing I can do to make my CTRF better” 
Emotional 
Representation: 
“My CTRF makes me feel angry” “I wish my CTRF would 
just go away” “My CTRF does not worry me” 
Identity: “Pain” “Difficulty falling asleep” “No desire to move” 
Timeline (Acute 
vs. Chronic and 
Cyclical): 
“I go through cycles in which my CTRF gets better and 
worse” 
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2. Describe the internal consistency reliability of the CTRFRep scale. 
Research Question 2a: What is the internal consistency reliability of the 
CTRFRep Acute vs. Chronic Timeline, Timeline Cyclical, Consequences, Cause, 
Personal Control, Treatment Control, Symptom Coherence, Emotional 
Representation, and Positive Consequences subscales? 
3. Describe the construct validity of the CTRFRep scale.  
Hypothesis 3a: The CTRF Identity subscale will show a significant difference 
between the symptoms experience subscale and those associated with CTRF 
(Moss-Morris, et al., 2002) 
Hypothesis 3b: CTRFRep subscales mediate the relationship between CTRF 
intensity and CTRF distress. 
Sample eligibility criteria. 
Following the obtaining of human subjects approval, 47 patients were recruited 
for this study over a 3-5 month period. In the event that recruitment progressed quickly, 
recruitment would end when the sample size was adequate (N=100) for the planned 
factor analysis. Patients were eligible for this study if: 
• They are older than 21 years of age 
• They are receiving external beam radiation for cancer AND the duration of the 
treatment is greater than three weeks 
• They are able to speak and read English. 
Exclusion criteria include: 
• Radiation treatment to the brain 
• Known brain metastases 
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The inclusion and exclusion criteria were developed after discussion with the medical 
director of the radiation oncology clinic and the clinic’s research nurse. The rationale for 
the exclusion criteria was that patients with known brain metastases or who were 
receiving whole-brain radiation would be more likely to have cognitive difficulties that 
would make assessing their beliefs and answering the questionnaires overly burdensome 
for them. 
Participant recruitment and enrollment. 
Participant recruitment and enrollment involved several steps: (a) identifying 
potentially eligible patients; (b) verifying eligibility criteria and patient receptiveness; and 
(c) approaching the patient regarding potential participation in the study. Research nurses 
at the radiation oncology clinic prepared a list of potentially eligible patients including 
patient names, appointment times, and treatment machine location. This list and its 
identifying information were not removed from the radiation oncology clinic. The 
Principal Investigator (PI) reviewed the list and eligibility criteria with therapists at the 
treatment machines and approached patients who may have been eligible for the study. 
The PI then briefly introduced the study. If the patient expressed interest in participating, 
the PI provided the patient with further information about the purpose and design of the 
study, and the requirements for participation. She obtained written informed consent and 
an authorization for release of health information for research from interested patients. 
Those who declined participation were immediately removed from the list of potential 
subjects.  
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Research Design, Methods and Procedures 
For this cross-sectional study, upon obtaining informed consent, the PI informed 
the Radiation Oncology Center’s staff of the patient’s willingness to participate in the 
study. Data collection occurred at the patient’s four-week follow-up appointment. This 
appointment was scheduled during the patient’s last radiation treatment. The Radiation 
Oncology Center staff informed the PI of the follow-up appointment date and time for 
consented patients. At the patient’s follow-up appointment, the PI collected data through 
a face-to-face interview in a private area of the radiation oncology office suite. 
Measures and data collection instruments 
Six instruments were used, including the CTRF Representation instrument 
(CTRFRep) that is being evaluated and several scales that were used to assess the 
construct validity of the CTRFRep. The instruments were the Positive and Negative 
Affect Scales (PANAS) (Watson, et al., 1988), the Center for Epidemiologic Studies-
Depression (CES-D) (Radloff, 1977), the Profile of Mood States–Short Form (POMS-SF) 
(McNair, Lorr, & Droppleman, 1992), the Multidimensional Fatigue Inventory (MFI-20) 
(Smets, Garssen, Bonke, & De Haes, 1995), and the Cancer Related Fatigue Distress 
Scale (CRFDS) (Holley, 2000b). Table 7 presents the operational definitions of all study 
variables, as well as the instrument and number of items in each scale. 
Demographic variables 
Demographic data were collected using an investigator-developed chart audit 
form addressing age, race, marital and employment status and spiritual affiliation. 
Disease and treatment information, including time since diagnosis, stage, and additional 
information such as hemoglobin levels, radiation type and dosage, and hormone dosages 
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were obtained from the medical record. This data was collected in order to describe the 
demographic characteristics of the sample. 
Psychological variables 
The Positive and Negative Affect Scale (PANAS) (Watson, et al., 1988) was used 
to measure trait positive and negative affect. The PANAS contains two 10-item scales. 
The items are on five-point scales anchored by “very slightly or not at all” to “very 
much” with higher scores indicating higher levels of positive or negative affect. The scale 
was administered with a temporal instruction (i.e. “In general, that is on the average”) 
intended to capture trait affect (Watson, et al., 1988). Cronbach alpha reliabilities for the 
general scale in a sample of 663 adults were .88 for PA and .87 for NA (Watson, et al., 
1988). In addition, the intercorrelation of PA and NA was -.17, indicating that the shared 
variance of the two scales was less than 3% (Watson, et al., 1988). Test-retest reliabilities 
for an 8-week interval were .68 (PA) and .71 (NA) for the general temporal instruction 
which was used in this study to assess trait positive and negative affect (Watson, et al., 
1988). 
The Center for Epidemiological Studies – Depression, (CES-D) Radloff, (1977) 
was used to measure depressive symptoms. The CES-D is a 20-item scale on which 
respondents rate the frequency of experienced symptoms on a 0-4 scale ranging from 
“Rarely or none of the time” to “Almost all the time” with higher scores indicating higher 
levels of depressive symptoms (Radloff, 1977). The scale has had Cronbach alpha 
reliabilities ranging from .85 to .90 (Radloff, 1977). In addition, the CES-D has 
advantages for use in cancer patients because it contains few somatic items 
(Andrykowski, et al., 1996).  
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Table 7 
Operational Definitions of Variables Used in the Study 
Concept Operational Definition/How measured Total Item N 
Affect 
Trait Positive and Negative Affect Scale 
(PANAS) 
20 items with 2 
subscales 
Depression 
Center for Epidemiological Studies-
Depression Scale (CES-D) 
20 items  
Fatigue Intensity 
Profile of Mood States short-
form_Fatigue (F_POMS-sf) 
5 items 
Multi-dimensional Fatigue Inventory 
(MFI-20) 
20 items with 5 
subscales 
Cancer Treatment-
Related Fatigue 
Representation 
Cancer Treatment Related Fatigue 
Representation (CTRFRep) Scale (See 
Table 4) 
105 total items with 10 
subscales 
Fatigue Distress 
Cancer-Related Fatigue Distress Scale 
(CRFDS) 
20 items 
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Fatigue intensity 
The Profile of Mood States short form (POMS-sf) - fatigue subscale (F_POMS-
sf) (McNair, et al., 1992) and the Multidimensional Fatigue Inventory (MFI-20) (Smets, 
et al., 1995) were used to measure CTRF intensity. Two scales were used for several 
reasons: 1)The NIH State of the Science Conference on Symptom Management in Cancer 
Patients has identified the need to “compare simple screening strategies with more 
complex screening and diagnostic approaches in clinical practice”(National Institutes of 
Health, 2002, p. 17). 2) The POMS-sf is an established, widely used scale with a brief 
(five-item) unidimensional measure of fatigue intensity (the F_POMS-sf). Thus, this brief 
scale may be more appropriate for clinical populations. In contrast, the MFI-20 is a 
relatively new scale that is multi-dimensional. 3) The dimensions measured in the MFI-
20 may correlate individually with the outcome measure of CTRF Distress, thus 
providing important information in testing the effects of mediating variables. 4) Testing 
these instruments concurrently in this population will allow determination of the possible 
benefit of additional information provided by the MFI-20 weighed against the cost of 
subject burden of additional items. 
The F_POMS-sf is a 5-item self-administered adjective checklist on a 5-point 
Likert scale. Subjects were directed to indicate how they felt during the last 7 days in 
relation to each adjective. Answer choices on the 0-4 scale are anchored by “not at all” 
and “extremely.” Thus, the range of scores is 0-20, with higher scores indicating more 
fatigue. The scale has had excellent internal consistency, from 0.93 to 0.94 in psychiatric 
outpatients (McNair, et al., 1992). In addition, ease of use and construct validity have 
been established in a population of adult patients with cancer (Meek, et al., 2000). 
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Although this fatigue scale is part of a larger scale measuring mood, it is not considered 
to be a pure measure of mood when used with patients experiencing physical illness (Nail 
& King, 1987). The POMS-sf, a 30-item scale, was administered in its entirety in order to 
maintain the integrity of the fatigue-inertia subscale score and the ability to compare the 
patients in the proposed study to other patients for whom the POMS-sf has been used to 
measure mood. 
The MFI-20 is a 20-item scale with five dimensions: general fatigue, physical 
fatigue, mental fatigue, reduced motivation, and reduced activity. The items are measured 
on 5-point scales anchored by “yes, that is true” and “no, that is not true” with higher 
scores indicating higher levels of fatigue (Smets, et al., 1995). The Cronbach alpha in 
patients undergoing radiation therapy has ranged from .77 for the metal fatigue subscale 
to .86 for the physical fatigue subscale. Construct validity was established by 
comparisons among various healthy and fatigued groups (Smets, et al., 1995). 
Cancer Treatment-Related Fatigue Representation (CTRFRep) 
The Cancer Treatment-Related Fatigue Representation Scale (CTRFRep) was 
used to measure CTRF representation. Qualitative research reports of the experience of 
CTRF, (Barsevick, Whitmer, & Walker, 2001; Mock, et al., 2000; Nail, 2002; Nail & 
King, 1987; Nail & Winningham, 1995; Ream & Richardson, 1996, 1997) illness 
perception, (Moss-Morris, et al., 2002; Weinman, Petrie, Moss-Morris, & Horne, 1996) 
and psychometric theory (Lyberg, 1997) guided the development of the CTRFRep. 
As shown in Table 4, and as tested in the present study, the CTRFRep consists of 
105 items in 10 subscales. The Identity subscale contains 26 items representing 
symptoms that patients may or may not have experienced since they began having CTRF. 
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Subjects are asked to endorse items (Yes or No) if they have had the symptom since they 
began having CTRF. If the answer for a given symptom (e.g., pain) is ‘Yes’ then the 
subject is asked whether he believes it is related to or contributes to his CTRF. The 
remaining subscales use a 5-point Likert-type scale with anchors of ‘strongly disagree’ to 
‘strongly agree.’ The Cause subscale contains 23 items representing things (e.g., Stress or 
worry, radiation treatment for cancer) subjects may or may not believe caused their 
CTRF. None of these items is reverse-scored. The Timeline Acute vs. Chronic subscale 
contains six items of which three are reverse scored. Higher scores indicate stronger 
belief that CTRF is chronic (i.e. long lasting), whereas lower scores indicate stronger 
belief that CTRF is acute. The Timeline Cyclical subscale contains four items, none of 
which is reverse scored. Higher scores indicate stronger belief that CTRF is predictable 
or cyclical, whereas lower scores indicate a stronger belief that CTRF is unpredictable. 
The Consequences subscale contains six items of which one is reverse-scored. Higher 
scores indicate a stronger belief that CTRF has negative consequences vs. lower scores, 
which indicate weaker belief that CTRF has negative consequences for the subject. The 
Personal Control subscale contains 16 items of which four are reverse scored. Higher 
scores reflect stronger belief in the subject’s own ability to control his/her CTRF. The 
Treatment Control subscale has seven items of which two are reverse-scored. Higher 
scores indicate a stronger belief that there are treatments available that can help control 
the subject’s CTRF. The Symptom Coherence scale contains six items of which four are 
reverse-scored. Higher scores indicate stronger belief in the subject’s ability to ‘make 
sense of’ his or her own experience of CTRF. The Emotional Representation scale 
contains seven items of which one is reverse-scored. Higher scores indicate stronger 
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negative emotional representations of fatigue. The Positive Consequences scale was 
developed by the author in an attempt to elicit any positively valenced consequences of 
the CTRF experience. This scale contains four items, of which none are reverse scored. 
Higher scores would indicate a stronger belief that there are some positive consequences 
that result from having CTRF.  
Fatigue distress 
The Cancer Related Fatigue Distress Scale (CRFDS) (Holley, 2000b) was used to 
measure CTRF Distress. The CRFDS was developed using content analysis of interviews 
with cancer patients. The instrument has 20 items on a 0-10 scale anchored by “no 
distress” and “severe distress” with higher scores indicating a higher level of fatigue 
distress. The items are summed and the mean is taken, resulting in a scale score of 0-10 
where higher scores indicate more fatigue distress. The CRFDS contains items addressing 
the physical, social, psychological, cognitive, and spiritual aspects of fatigue distress. 
This single-factor scale has strong internal consistency with a reported alpha coefficient 
of 0.98 (Holley, 2000b). Construct validity was established when all items loaded on a 
single factor representing fatigue distress. 
Statistical analyses 
Preliminary analysis: Prior to any data analysis, the data were screened using 
frequency analyses for normality and outliers will be identified. Distributions that are 
highly skewed were evaluated for possible standardization of scores. 
Specific Aim #1: Identify the factor structure of the CTRFRep Scale. 
Research Question 1a: What is the factor structure of the CTRFRep Cause 
subscale? 
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Although sample size is smaller than recommended for factor analysis (minimum 
3 subjects per item, with some recommending up to 10 subjects per item) this is the initial 
study of the instrument. In addition, it should be noted that the items on the Cause 
subscale were factored separately from the other items. Thus, the maximum number of 
items entered into factor analysis would be 54 items. There is some argument that factor 
analyses can be used with sample sizes as low as 50-100 subjects if there are at least 5 
items per subscale to be factored (Sapnas & Zeller, 2002)  
Research Question 1b: What is the factor structure of the Timeline, 
Consequences, Control, Symptom Coherence, and Emotional Representation subscales? 
In terms of the remaining subscales, several steps are involved in identifying the 
factor structure of the CTRFRep Scale. The Cause subscale contains 23 items that were 
analyzed using principal components analysis (PCA). Pett, Lackey, and Sullivan (2003) 
recommend that items analyzed with PCA either be standardized or measured on a 
similar scale. Because the Cause items share a common 5-point Likert-type scale, the 
analysis plan will not include standardization of the scores. The Cause subscale is entered 
into a separate PCA because it is expected that the analysis will result in identification of 
factors structured around beliefs about the causes of CTRF (Moss-Morris, et al., 2002). 
For example, one could hypothesize the emergence of a “treatment component” which 
could include “My chemotherapy treatment for cancer” and “My radiation treatment for 
cancer.” The purpose of the PCA of the Cause subscale is to identify items that are 
relevant to patients with CTRF and those that are less relevant. After completion of the 
PCA, causal items may be deleted from the final scale. The criteria for item deletion 
include 1) lack of face validity in the experience of CTRF, 2) item did not load on any 
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factor or loaded on multiple factors, and 3) item not endorsed by at least 10% of the 
sample. 
Principal components exploratory factor analysis (PCEFA) will be used to 
evaluate the factor structure of the Timeline Acute/Chronic, Timeline Cyclical, 
Consequences, Personal and Treatment Control, Symptom Coherence, Emotional 
Representation, and Positive Consequences scales. In an iterative process, the first 
analysis will include all 56 items in these scales in a PCEFA. Preliminary inclusion 
criteria for retaining factors will include Eigenvalues>1.0 and evaluation of Scree plots. 
Items loading on multiple factors will be evaluated for deletion from the scale. 
Subsequent iterations will evaluate the factor loadings of individual items with criteria of 
0.4-0.5 considered satisfactory loading on a single factor. 
Specific Aim #2: Describe the internal consistency reliability of the CTRFRep 
Scale 
Research Question 2: What is the internal consistency reliability of the CTRFRep 
Identity, Cause, Timeline Acute vs. Chronic, Timeline Cyclical, Consequences, Personal 
Control, Treatment Control, Symptom Coherence, Emotional Representation, and 
Positive Consequences subscales? 
The sample size of 47 is adequate to perform Pearson correlations and internal 
consistency reliability. If alpha was low, items were assessed to evaluate their 
contribution to the overall alpha coefficient. Items with low (<0.30) or high (>0.70) item-
to-total correlations were evaluated for deletion from the scale for low coherence or 
redundancy. In terms of the internal consistency reliability of the subscales, scales with a 
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high (>0.90) Cronbach alpha were evaluated for redundant items in order to reduce the 
total number of items in the scale. 
Specific Aim #3: Describe the construct validity of the CTRFRep scale. 
Hypothesis 3a: The CTRFRep Identity subscale will show a significant difference 
between the symptoms experience subscale and those associated with CTRF (Moss-
Morris, et al., 2002) 
The Identity subscale consists of a series of symptoms for which the subject 
indicates yes or no as to whether a) the symptom has been present since the subject has 
had CTRF and b) whether the subject believes the symptom is related to or contributes to 
the patient’s CTRF. The Identity subscale is the only subscale that was not evaluated 
using factor analytic techniques. Instead, frequency analyses identified which symptoms 
were endorsed as causes of their fatigue. Symptoms that were endorsed by a relatively 
low number of subjects will be candidates for deletion from the final scale. In addition, 
paired samples t-tests were used to identify differences in beliefs about the presence of 
symptoms and their contribution to their CTRF. This provided information about whether 
subjects believed that certain symptoms were related to their CTRF but not others. 
Hypothesis 3b: CTRFRep subscales mediate the relationship between CTRF 
intensity and CTRF distress. 
Construct validity of items used to measure CTRFRep was tested by using a 
mediation model in which the components of CTRFRep were hypothesized to mediate 
the relationship between CTRF intensity and CTRF distress. As described by Baron & 
Kenny (1986), mediating variables account for the correlation of predictor and criterion 
variables. In this study, the mediating variables of the CTRFRep subscales were 
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hypothesized to account for the relation between CTRF intensity (after controlling for 
negative affect and depressive symptoms) and CTRF distress. In this analysis, the 
CTRFRep subscales functioned as mediating variables if the following conditions were 
met: (a) variations in the level of CTRF intensity accounted for variations in CTRFRep 
subscale scores; (b) variations in CTRFRep subscale scores significantly accounted for 
variations in CTRF distress; and (c) when CTRFRep subscale scores were controlled, a 
previously significant relationship between CTRF intensity and CTRF distress was no 
longer be significant, with the strongest demonstration of mediation occurring if the 
relationship between CTRF intensity and CTRF distress equaled zero (Baron & Kenny, 
1986). In terms of the analysis plan, the intercorrelation of the PANAS, CES-D and 
CTRF intensity, finalized CTRFRep subscales and CTRF distress will be evaluated using 
Pearson correlations.  
The analysis plan included the following multiple linear regressions: 
Model 1: The PANAS and CES-D entered in to the analysis as independent 
variables, with CTRF distress entered as the dependent variable. 
Model 2: The PANAS and CES-D (Block I) entered first, followed by CTRF 
intensity (Block II) as independent variables, with CTRF distress as the dependent 
variable.  
Model 3: Mediation model PANAS and CES-D (Block I), CTRF intensity in 
(Block II), CTRFRep subscales (Block III), and CTRF distress as the dependent variable. 
It is hypothesized that the variance accounted for by the effect of CTRF intensity 
on CTRF distress will be less in Model 3 than in Model 2.  
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CHAPTER 4: RESULTS 
Introduction 
Chapter 4 consists of three major sections. The first section deals with the 
procedures for data cleaning. The second portion deals with description of the study 
variables, including reliability analyses of all scales and subscales exclusive of the 
CTRFRep. The final section involves answering research questions and testing 
hypotheses regarding the CTRFRep.  
Data Cleaning 
Data for this study were collected using two primary methods. Questionnaire data 
was collected via in-person interviews of patients that took place in the radiation 
oncology clinic. Medical record audits were used to gather demographic data and disease 
and treatment information. All data were coded with a subject identification number and 
entered into the SPSS statistical software program (SPSS, 2009). Data were checked for 
accuracy of input. In addition, univariate statistics were examined for means, standard 
deviations, outliers and out-of-range values (Tabachnick & Fidell, 2001). Any errors 
discovered were corrected using the original interview form. Missing values in the 
interview data were rare and mean substitution was used to correct this. Missing data 
from the medical audit data is more frequent, and will be explained further presently. 
However, analysis using these variables is limited to univariate descriptives to describe 
the sample.  
All independent and dependent study variables were assessed for normality using 
a Shapiro-Wilk test using a p value of 0.05. This test is appropriate for small sample sizes 
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(N<50) (Field, 2009). Further discussion of normality and transformations will be 
undertaken when describing the study variables.  
Description of Study Variables 
Table 8 provides descriptive statistics for the demographic and treatment variables 
for the sample. Table 9 presents descriptive statistics for all variables included in the 
questionnaire aside from the variables in the CTRFRep. Descriptive statistics for the 
CTRFRep are presented later in this chapter (see Table 29).  
Sample Considerations 
The sample consists of 47 patients who received external beam radiation 
treatment for cancer. Of these 47 patients, 36 patients (77%) experienced fatigue during 
their cancer treatment. These patients completed the entire interview packet. However, 
those patients who did not experience fatigue answered neither the questions for the 
CTRFRep nor the questions for the CRFDS. Also, as of this writing, the missing medical 
record audit data mentioned above is largely due to the fact that chart audits were not 
complete for patients who did not experience fatigue during their treatment. 
To clarify explanation of the variables and analyses, when discussing ‘the sample’ 
the writer is referring to the entire sample of 47 subjects. When discussing the ‘fatigued 
(sub-)sample’ the writer is referring to the sample of 36 patients who experienced fatigue 
during their treatment for cancer. Finally, when referring to the ‘non-fatigued (sub) 
sample’ the writer is referring to the 11 patients who did not experience fatigue during 
their cancer treatment.  
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Demographic and Treatment Variables 
Demographic and treatment variables were collected using medical record audits. 
Table 8 presents a summary of the demographic and treatment information.  
Depressive symptoms 
Depressive symptoms were measured using the CES-D scale. Items on the scale 
were recoded as necessary so that higher scores indicate higher levels of depression. 
Table 9 presents the measures of central tendency for the CES-D. The mean level of 
depressive symptoms in the group was 14.43, suggesting a moderate level of depressive 
symptoms. Using the z distribution, scores in the full sample exhibited a significant 
positive skew (z=2.2; p<0.05) but minimal kurtosis. However, in the fatigued sample, the 
positive skewness decreased to a non-significant level (z=1.13). 
Positive and Negative Affect 
Positive and Negative Affect (PA and NA) were measured using the Positive and 
Negative Affect Scale (PANAS). Higher scores indicated higher levels of positive and 
negative affect, respectively. Mean scores were calculated for the entire sample as well as 
the subsamples. Using the z distribution, the scores for positive affect showed non-
significant negative skewness and kurtosis. The scores for negative affect showed non-
significant positive skewness and negative kurtosis.  
Cancer Treatment-Related Fatigue Intensity 
Cancer treatment-related fatigue intensity was measured using two scales, the 
Multidimensional Fatigue Inventory (MFI-20) and the Profile of Mood States Short-
Form_Fatigue (F_POMS-sf). Items on the MFI-20 were recoded according to instructions 
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Table 8.  
 
Sample Descriptive Statistics  
 
Construct Mean (SD)  Construct Category N  % 
Age 57.7(11.4) 
years 
Gender Male 23 49 
Hemoglobin 13.34 (1.60) 
gm/dl 
Radiation 
Dose 
5967 (1092) 
cGy 
Female 24 51 
 Race Caucasian 42 89 
African-American 5 11 
Ethnicity Latino 1 2 
Non-Latino 46 98 
Marital Status Married 18 38 
Unmarried 4 9 
Divorced 5 11 
Widowed 1 2 
Unknown 19 40 
Employment 
Status 
Full- or Part-Time 16 34 
Retired 5 11 
Not Employed 4 9 
Unknown 22 46 
Cancer Site Breast 14 30 
Prostate 7 15 
Head and Neck 6 13 
Colorectal/Anal 3 6 
Other Site 6 13 
Unknown 11 23 
Cancer Stage Stage 0 2 4 
Stage I 6 13 
Stage II 5 11 
Stage III 10 21 
Stage IV 5 11 
Unknown 19 44 
Cancer 
Treatments 
External Beam Radiation 47 100 
Surgery  16 34 
Chemotherapy 14 30 
Hormone Treatment 1 2 
Disease Status Primary Cancer 34 72 
Recurrent Disease 2 4 
Unknown 11 23 
Fatigue Before 
Cancer Diagnosis 
No 33 70 
Yes 11 24 
Unknown 3 6 
Fatigue During 
Cancer 
Treatment 
Yes 36 77 
No 11 23 
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provided by the author of the scale so that higher scores reflect more fatigue (Smets, 
2002; Smets, et al., 1995). A summed score was computed for each of the five subscales 
of the MFI-20. All of these subscale scores demonstrated non-significant negative 
kurtosis and positive skewness using the z distribution. The F_POMS-sf was calculated 
as a summed score of all variables in the subscale. The scores for the F_POMS-sf showed 
non-significant positive skewness and significant (z=1.96; p=.05) negative kurtosis using 
the z distribution.  
Cancer Treatment-Related Fatigue Distress 
Cancer treatment-related fatigue distress was measured using the CRFDS. The 
scale score was calculated by summing all variables and calculating the mean score for 
each individual. The scale scores showed a non-significant positive skewness and nearly 
significant (z=-1.91) negative kurtosis.  
The dependent variable fatigue distress (CRFDS) was found to be significantly 
non-normal (p=0.005). Logarithmic (ln) transformation of the variable was suggested 
after consultation with a statistician. Unfortunately, the LN transformation failed to 
correct the normality and, in consultation with the statistician it was suggested that the 
variable be dichotomized . 
Comparison of fatigued and non-fatigued groups 
As a manner of testing the validity of the instruments used in this study, non-
parametric testing was undertaken to compare the median levels of variables among the 
36 fatigued and 11 non-fatigued subjects in the study. Table 10 reveals that all but two 
subscales had significantly different medians – in the expected directions – using the  
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Table 9. 
 
Descriptive Statistics for Non-CTRFRep Variables 
Instrument Subscale Item N 
Mean 
(SD) Median 
Actual Range 
(Possible 
Range) 
Skewness Kurtosis Cronbach’s Alpha 
MFI-20 
General Fatigue 4 11.28 (4.95) 10.50 
4-20 
(4-20) .15 -1.14 .87 
Physical Fatigue 4 10.87 (4.51) 10.50 
4-20 
(4-20) .24 -1.07 .84 
Reduced Activity 4 10.04 (4.71) 9.00 
4-20 
(4-20) .58 -.75 .90 
Reduced Motivation 4 8.52 (3.78) 8.00 
4-17 
(4-20) .63 -.53 .69 
Mental Fatigue 4 9.37 (5.11) 8.00 
4-20 
(4-20) .53 -.98 .92 
POMS 
Tension/ 
Anxiety 5 
5.80 
(4.74) 5.00 
0-16 
(0-20) .60 -.68 .87 
Depression/ 
Dejection 5 
4.48 
(4.72) 3.00 
0-16 
(0-20) .93 -.30 .89 
Anger/ 
Hostility 5 
5.46 
(5.22) 4.00 
0-20 
(0-20) .99 .24 .95 
Vigor/ 
Activity 5 
9.65 
(5.48) 10.00 
0-20 
(0-20) .06 -.89 .95 
Fatigue/ 
Inertia 5 
7.37 
(5.97) 6.5 
0-18 
(0-20) .25 -1.34 .95 
Confusion/ 
Bewilderment 5 
5.07 
(3.74) 5.00 
0-13 
(0-20) .50 -.83 .84 
PANAS 
Positive Affect 10 38.61 (7.87) 40 
19-50 
(5-50) -.42 -.56 .94 
Negative Affect 10 18.91 (6.61) 17 
10-33 
(5-50) .56 .69 .88 
CRFDS* Cancer Fatigue Distress 20 
3.76 
(2.99) 3.8 
0-9 
(0-10) .14 -1.47 .98 
CES-D Depressive Symptoms 20 
14.43 
(12.76) 12.00 
0-48 
(0-60) .73 -.30 .94 
Sample N=47 
*Sample N=36 
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Mann-Whitney U test. The two subscales that did not have significant differences were 
the positive affect scale and the MFI reduced motivation subscale.  
 It is expected that the positive affect subscale would not differ significantly based 
on levels of cancer treatment-related fatigue. However, the non-significant results for the 
MFI reduced motivation subscale are somewhat surprising. There are at least two 
hypotheses as to why this result was not significant: 1) small sample size and 2) the items 
on this subscale include ‘I have a lot of plans’ and ‘I feel like doing all sorts of nice 
things,’ which may be more often rated as true for patients in spite of their cancer 
treatment-related fatigue.  
Research Questions and Hypothesis Testing 
The following section will deal with analyzing the research questions and testing 
the hypotheses of the study. All statistical analyses used the PASW statistical software 
package, Version 17.0.2 (SPSS, 2009). 
Specific Aim #1: Identify the factor structure of the CTRFRep Scale 
Research Question 1a: What is the factor structure of the CTRFRep Cause 
subscale? 
In order to answer this research question, the 23 items in the Cause subscale were 
entered into a principal components analysis with Varimax rotation. The results of this 
analysis were not definitive and suggest that a larger sample size will be needed in order 
to properly factor the CTRFRep Cause subscale. The specific issues with the factor 
analysis include: 
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Table 10. 
 
Comparison of Fatigued and Non-Fatigued Groups 
Instrument Subscale Fatigued Median Mann-Whitney U z-score Exact Sig. 
MFI-20 
General Fatigue 
No 6.00 
53.00 -3.66 .000 
Yes 13.50 
Physical Fatigue 
No 8.00 
83.50 -2.89 .003 
Yes 11.00 
Reduced Activity 
No 6.00 
98.00 -2.52 .011 
Yes 10.00 
Reduced Motivation 
No 7.00 
153.50 -1.12 .268 
Yes 9.00 
Mental Fatigue 
No 5.00 
116.00 -2.10 .039 
Yes 10.00 
POMS 
Vigor/ 
Activity 
No 14.00 
87.00 -2.80 .004 
Yes 8.00 
Fatigue/ 
Inertia 
No 0.00 
40.50 -3.98 .000 
Yes 10.00 
PANAS 
Positive Affect 
No 44.00 
149.00 -1.23 .227 
Yes 39.00 
Negative Affect 
No 12.00 
58.00 -3.53 .000 
Yes 19.50 
CES-D Depressive Symptoms 
No 2.00 
57.50 -3.54 .000 
Yes 15.50 
Sample N=36 
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1) The determinant of the correlation matrix was 2.44E-008. This is smaller than 
the value of 0.00001 recommended as the minimum value for a satisfactory 
correlation matrix (Field, 2009).  
2) The Kaiser-Meyer-Olkin (KMO) measure of sampling adequacy test statistic 
– which has values between 0 and 1.0 – was 0.477. According to Kaiser, as 
cited in Pett, Lackey and Sullivan (2003), KMO test statistics of less than 0.60 
are “mediocre, miserable or unacceptable” (p. 70). According to Kaiser as 
cited in Field (2009) values of 0.50 are “barely acceptable” and should lead 
one to collect more data or rethink variable selection. According to Field 
(2009) values near 0 mean that the “sum of partial correlations is large relative  
to the sum of correlations…[and as a result]… factor analysis is likely to be 
inappropriate (p. 647).” 
3) Bartlett’s test of sphericity had a negative value for its Chi-Square test 
statistic, which violates the assumptions of the Chi-Square distribution and 
suggests that the correlation matrix is an identity matrix, which would make 
interpretation of factor analyses ill-advised (Field, 2009). 
For these reasons, the results of the factor analysis are not presented here. Instead, 
Table 11 shows the percentage of subjects who answered either ‘agree’ or ‘strongly 
agree’ for each of the Cause items. According to the criteria laid out in the previous 
chapter, two items – ‘chance or bad luck’ and ‘accident or injury’ – will be deleted from 
the Cause subscale in future analysis because they were endorsed by less than 10% of the 
respondents. In terms of the face validity of the Cause subscale, subjects identified items 
such as ‘hereditary, it runs in my family’ and ‘poor medical care in the past’ as causes for 
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cancer treatment-related fatigue. When evaluating face validity, these items may be more 
likely viewed as causes of cancer itself versus CTRF. Therefore, consideration will be 
given to removing these items from the subscale in future analyses. In addition, 
instructions for this section of the interview may be revised to stress the idea that the 
questions refer to causes of their cancer treatment-related fatigue, not causes of the cancer 
itself. 
Research Question 1b: What is the factor structure of the Timeline, 
Consequences, Control, Symptom Coherence, and Emotional Representation subscales? 
As with the previous research question, items from these subscales were entered 
into a Principal Components Analysis. However, prior to doing so, all subscales were 
tested for internal consistency reliability (See Specific Aim #2, Research Question 2a for 
more detail as to the method and results of these analyses). After the reliability analysis 
was used to reduce the number of items entered into factor analysis, 34 items were 
entered into a Principal Components Analysis with Varimax rotation. As with the Cause 
subscale, the analysis was not definitive and suggests that more data will need to be 
collected before evaluating the scale using factor analysis. Specific issues with this 
analysis were: 
1) The determinant of the matrix was 4.34E-023, which is substantially smaller 
than the recommended value of 0.00001 (Field, 2009). 
2) The KMO test statistic was 0.271, well below the acceptability threshold 
(Field, 2009). 
For these reasons, the results of the factor analysis are not presented here, and no 
further item reduction will take place at this time. 
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Table 11. 
 
Summary Statistics for CTRFRep Cause Subscale * 
 
My chemotherapy treatment for cancer** 96% 
Having cancer 94% 
My radiation treatment for cancer** 83% 
My surgical treatment for cancer** 73% 
My hormone treatment for cancer** 67% 
Stress or worry 61% 
Diet or eating habits 58% 
Aging 56% 
Altered immunity 53% 
My emotional state 47% 
My own behavior 39% 
My mental attitude 33% 
Overwork 33% 
Family problems or worries 31% 
My personality 31% 
Heredity 28% 
Smoking 28% 
Pollution in environment 19% 
Alcohol 15% 
Germ or virus 14% 
Poor medical care in past 11% 
Chance or bad luck 8% 
Accident or injury 6% 
*Cronbach’s Alpha =.65 
 
**Valid percent – i.e. percentage of those who had this type of treatment for their cancer 
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Specific Aim #2: Describe the internal consistency reliability of the CTRFRep 
Scale 
Research Question 2: What is the internal consistency reliability of the CTRFRep 
Identity, Cause, Timeline Acute vs. Chronic, Cyclical Timeline, Consequences, Personal 
Control, Treatment Control, Symptom Coherence, Emotional Representation and Positive 
Consequences subscales? 
In order to answer this research question, each set of items for the hypothesized 
subscales was entered into a separate reliability analysis. Table 11 presents the Cronbach 
alpha for the Cause subscale. The reported value of 0.65 is lower than the recommended 
value of 0.70. However, there are several possible reasons for this: 1) the scale has not 
been factor analyzed; 2) as a result of this, the scale is not additive – there is not a linear 
relationship between the individual scores and the total score. This violates one of the 
assumptions of reliability testing (SPSS, 2009).  
The results for the Identity subscale are presented in Table 12. The Kuder-
Richardson 20 statistic for the scale was 0.86. Tables 13-28 present the correlation 
matrices and item statistics for all of the CTRFRep subscales. Table 29 presents the 
descriptive statistics for the subscale scores of the CTRFRep as they are following the 
internal consistency reliability testing. Table 30 shows the items retained in after several 
iterations of reliability analysis and item deletion. Table 31 shows the two subscales (see 
next paragraph) that did not have adequate internal consistency reliability, as well as the 
items that were deleted from the subscales during reliability testing.  
The Treatment Control and Timeline Cyclical subscales had poor alpha 
coefficients (α<=.52). Further examination of these subscales finds that these results are 
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not unexpected. The Treatment Control subscale has items that deal with beliefs about 
medications and treatments for CTRF, but there are few treatments for CTRF. In order to 
evaluate the possible utility of the Treatment Control items, they were added to the 
Personal Control items and evaluated for deletion along with those items. Two Treatment 
Control items were retained in the Personal Control subscale as it was entered into the 
factor analysis.  
The Timeline Cyclical subscale deals with beliefs about the cyclical nature of 
CTRF. There are a couple of reasons why this subscale may not be internally consistent 
in this sample of patients with CTRF. First, there is a small sample size. Second, this is a 
heterogeneous sample of patients who had various treatments aside from radiation 
treatment for their cancer. It also may be that beliefs about periodicity may not be 
relevant for CTRF. Further testing would be needed in other samples to verify the reasons 
for the lack of internal consistency reliability for this subscale.  
As shown in Tables 29 and 30, at the end of the reliability analyses, all subscales 
had Cronbach alpha coefficients of at least 0.85 except for Positive Consequences, a 
three-item subscale that has an alpha of 0.70. Table 31 shows the two subscales with the 
low Cronbach alpha coefficients, as well as the other items that were deleted from the 
subscales as a result of reliability testing. Following reliability testing, the 56 items that 
were part of the non-Cause and non-Identity subscales were reduced to 34 items. The 
primary reason for deletion of items from the scale was either high or low inter-item 
correlations. Preference for retention of items was given to those items based upon items 
that were in the original IPQ-R. 
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Table 12. 
 
Identity Subscale* – Percentage of Sample Endorsing the Symptom as Related to or  
 
Contributing to CTRF 
 
Symptom % 
Lack of energy 92% 
Loss of strength 69% 
Feeling blue 60% 
Sadness 58% 
Poor concentration 56% 
Short attention span 53% 
No desire to move 53% 
Falling asleep 50% 
Staying asleep 50% 
Pain 47% 
Muscle weakness 47% 
Weight loss 42% 
Upset stomach 42% 
Loss of appetite 42% 
Difficulty moving 42% 
Heavy limbs 39% 
Nausea 34% 
Dizziness 33% 
Breathlessness 31% 
Difficulty waking up 31% 
Muscle soreness 31% 
Low endurance 31% 
Stiff joints 28% 
Headache 22% 
Wheeziness 19% 
Numbness 17% 
* Kuder-Richardson 20 reliability =.86  
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Table 13. 
 
Correlation matrix for CTRFRep Timeline Acute vs. Chronic Subscale Items 
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Short time*  0.43 0.81 0.61 0.41 0.22 
Permanent   0.64 0.68 0.85 0.72 
Long Time    0.66 0.61 0.36 
Pass Quickly*     0.62 0.43 
Rest of Life      0.74 
Improve in 
Time* 
      
* Reverse Scored Variable 
 
 
 
 
Table 14. 
 
Item Statistics for CTRFRep Timeline Acute vs. Chronic Subscale 
 
 Mean SD Corrected 
Item-Total 
Correlation 
Alpha if 
Item 
Deleted 
Short Time* 2.42 1.16 0.63 0.89 
Permanent 1.86 0.87 0.81 0.86 
Long Time 2.39 1.13 0.79 0.86 
Pass Quickly* 2.64 1.07 0.75 0.86 
Rest of Life 1.72 0.91 0.77 0.86 
Improve in Time* 1.83 0.74 0.56 0.89 
* Reverse Scored Variable 
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Table 15. 
 
Correlation Matrix for CTRFRep Timeline Cyclical Subscale Items 
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Changes Day to Day  0.49 0.20 0.22 
Pattern   -0.16 0.35 
Unpredictable    0.19 
Cycles     
 
 
 
 
 
Table 16. 
 
Item Statistics for CTRFRep Timeline Cyclical Subscale 
 
 Mean SD Corrected 
Item-Total 
Correlation 
Alpha if 
Item 
Deleted 
Changes Day to Day 3.31 1.09 0.46 0.30 
Pattern 2.78 0.93 0.34 0.43 
Unpredictable 3.08 1.05 0.12 0.62 
Cycles 3.33 1.01 0.37 0.40 
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Table 17. 
 
Correlation Matrix for CTRFRep Consequences Subscale Items 
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Serious Symptom  0.65 0.58 0.41 0.44 0.28 
Major Consequences   0.80 0.21 0.66 0.57 
Not much effect*    0.21 0.51 0.45 
Others reaction to me     0.39 0.34 
Financial Consequences      0.65 
Affects those close to me       
* Reverse Scored Variable 
 
 
 
 
 
 
Table 18. 
 
Item Statistics for CTRFRep Consequences Subscale 
 
 Mean SD Corrected 
Item-Total 
Correlation 
Alpha if 
Item 
Deleted 
Serious Symptom 3.19 1.19 0.62 0.83 
Major Consequences 3.08 1.23 0.80 0.79 
Not much effect* 3.33 1.31 0.69 0.81 
Others reaction to me 2.75 1.05 0.38 0.87 
Financial Consequences 2.56 1.25 0.71 0.81 
Affects those close to me 2.92 1.16 0.50 0.83 
* Reverse Scored Variable 
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Table 19. 
 
Correlation Matrix for CTRFRep Personal Control Subscale Items 
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Can do a lot  0.38 0.25 0.30 0.46 0.14 0.32 0.49 0.30 0.29 
I determine   0.43 0.35 0.29 0.39 0.40 0.47 0.56 0.53 
Depends on me    0.29 0.31 0.38 0.19 0.27 0.46 0.41 
Nothing I do*     0.37 0.64 0.54 0.70 0.50 0.30 
I have power      0.22 0.42 0.36 0.27 0.24 
No effect*       0.51 0.69 0.46 0.41 
Nothing can be done*        0.67 0.48 0.39 
Nothing can help*         0.52 0.49 
Diet          0.61 
Well-balanced meals           
* Reverse Scored Variable 
 
 
 
Table 20. 
 
Item Statistics for CTRFRep Personal Control Subscale 
 
 Mean SD Corrected 
Item-Total 
Correlation 
Alpha if 
Item 
Deleted 
Can do a lot 3.03 1.13 0.48 0.85 
I determine 3.08 0.88 0.62 0.83 
Depends on me 3.61 0.96 0.47 0.85 
Nothing I do* 4.06 0.58 0.62 0.84 
I have power 3.67 0.89 0.49 0.85 
No effect* 4.06 0.53 0.58 0.84 
Nothing can be done* 4.11 0.71 0.61 0.83 
Nothing can help* 4.28 0.66 0.74 0.82 
Diet 4.00 0.59 0.67 0.83 
Well-balanced meals 3.78 0.72 0.58 0.84 
* Reverse Scored Variable 
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Table 21. 
 
Correlation Matrix for CTRFRep Treatment Control Subscale Items 
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Nothing can be done*  0.04 0.20 0.66 0.25 0.31 
Medications   -0.28 -0.03 0.33 0.18 
Avoid negative    0.43 -0.20 -0.20 
Nothing can help*     0.05 0.23 
MD knows      0.30 
Asked MD       
* Reverse Scored Variable 
 
 
 
 
 
Table 22. 
 
Item Statistics for CTRFRep Treatment Control Subscale 
 
 Mean SD Corrected 
Item-Total 
Correlation 
Alpha if 
Item 
Deleted 
Nothing can be done* 4.11 0.71 5.45 0.24 
Medications 3.06 0.86 0.05 0.51 
Avoid Negative 3.06 0.96 -0.06 0.59 
Nothing can help 4.28 0.66 0.53 0.26 
MD knows 3.72 0.66 0.26 0.40 
Asked MD 2.53 9.10 0.25 0.39 
* Reverse Scored Variable 
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Table 23. 
 
Correlation Matrix for CTRFRep Symptom Coherence Subscale Items 
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Puzzling*  0.63 0.56 0.42 
Don’t understand*   0.80 0.68 
Makes no sense*    0.61 
Clear picture     
* Reverse Scored Variable 
 
 
 
 
 
Table 24. 
 
Item Statistics for CTRFRep Symptom Coherence Subscale 
 
 Mean SD Corrected 
Item-Total 
Correlation 
Alpha if 
Item 
Deleted 
Puzzling* 3.17 1.11 0.60 0.87 
Don’t understand* 3.42 1.05 0.84 0.77 
Makes no sense* 3.58 1.00 0.77 0.80 
Clear Picture 3.47 1.00 0.64 0.85 
* Reverse Scored Variable 
 
 
  
 76 
 
Table 25. 
 
Correlation Matrix for CTRFRep Emotional Representation Subscale Items 
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Depressed  0.66 0.55 0.77 0.57 
Angry   0.75 0.64 0.74 
Does not worry*    0.70 0.66 
Anxious     0.61 
Afraid      
*Reverse Scored Variable 
 
 
 
 
Table 26. 
 
Item Statistics for CTRFRep Emotional Representation Subscale 
 
 Mean SD Corrected 
Item-Total 
Correlation 
Alpha if 
Item 
Deleted 
Depressed 2.58 1.13 0.73 0.89 
Angry 2.42 0.97 0.81 0.88 
Does not worry* 2.61 1.10 0.76 0.89 
Anxious 2.78 1.07 0.80 0.88 
Afraid 2.39 0.96 0.74 0.89 
* Reverse Scored Variable 
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Table 27. 
 
Correlation Matrix for CTRFRep Positive Consequences Subscale Items 
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Time with family  0.47 0.44 
Take it easy   0.45 
Some good from    
 
 
 
 
Table 28. 
 
Item Statistics for CTRFRep Positive Consequences Subscale 
 
 Mean SD Corrected 
Item-Total 
Correlation 
Alpha if 
Item 
Deleted 
Time with family 2.97 0.97 0.53 0.60 
Take it easy 2.72 0.91 0.54 0.60 
Some good from 2.83 1.21 0.51 0.64 
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Table 29. 
 
Descriptive Statistics for CTRFRep Subscales 
 
Subscale Item N Mean 
(SD) 
Median Actual Range 
(Possible Range) 
Skewness Kurtosis Cronbach’s 
Alpha 
Identity 26 14.86 
(5.33) 
16 5-23 
(0-26) 
-0.31 -1.137 0.86* 
Timeline 
Acute vs. 
Chronic 
6 12.86 
(4.77) 
12.5 6-24 
(6-30) 
0.62 -0.20 0.89 
Consequences 6 17.83 
(5.44) 
18 6-29 
(6-30) 
-0.21 0.06 0.85 
Personal 
Control 
10 38.42 
(5.16) 
39 24-50 
(10-50) 
-0.43 1.12 0.85 
Symptom 
Coherence 
4 13.64 
(3.50) 
14.5 4-20 
(4-20) 
-0.72 0.35 0.86 
Emotional 
Representation 
5 12.78 
(4.48) 
12 5-20 
(5-25) 
0.20 -0.82 0.91 
Positive 
Consequences 
3 8.53 
(2.47) 
8 3-13 
(3-15) 
-0.05 -0.50 0.70 
*K-R 20 test statistic 
Sample N=36 
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Table 30. 
 
CTRFRep Subscale Items Retained for Factor Analysis with Subscale Cronbach Alpha  
 
Reliabilities 
 
Timeline Acute/Chronic (α=.89) 
My CTRF will last a short time (r) 
My CTRF is likely to be permanent 
My CTRF will last for a long time 
My CTRF will pass quickly (r) 
I expect to have CTRF for the rest of my life 
My CTRF will improve in time (r) 
Consequences (α=.85) 
 My CTRF is a serious symptom 
 My CTRF has major consequences on my life 
 My CTRF does not have much effect on my life (r) 
 My CTRF strongly affects the way others respond to me 
 My CTRF has serious financial consequences 
 My CTRF causes difficulties for those who are close to me 
*Control (α=.85) 
 I can do a lot to control my CTRF 
 What I do will determine whether my CTRF gets better or worse 
 The course of my CTRF depends on me 
 Nothing I do will affect my CTRF (r) 
 I have the power to influence my CTRF 
 My actions have no affect on my CTRF (r) 
 **Nothing can be done to improve my CTRF (r) 
 I believe that eating a healthy diet with help my CTRF 
 **There is nothing which can help my CTRF (r) 
 Eating well-balanced meals helps my CTRF 
Symptom Coherence (α=.86) 
 My CTRF is puzzling to me (r) 
 I don’t understand my CTRF (r) 
 My CTRF doesn’t make any sense to me (r) 
 I have a clear picture or understanding of my CTRF 
Emotional Representation (α=.91) 
 I get depressed when I think about my CTRF 
 My CTRF makes me feel angry 
 My CTRF does not worry me (r) 
 Having CTRF makes me feel anxious 
 Having CTRF makes me feel afraid 
Positive Consequences (α=.70) 
 My CTRF helps me spend more time with my family 
 I can “take it easy” because I have CTRF 
 All things considered, some good things have come from having CTRF 
 
(r) = items reverse scored 
*Personal and Treatment Control subscales combined 
**Treatment Control subscale items  
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Table 31.  
 
CTRFRep Items and Subscales Deleted before Factor Analysis 
 
Subscale 
(Cronbach Alpha) 
Item Reason for deletion 
Timeline Cyclical 
(α=.52) 
My CTRF changes a great deal from day to day Low Cronbach alpha 
reliability  My CTRF comes and goes in a pattern 
My CTRF is unpredictable 
I go through cycles in which my CTRF gets better and worse 
Treatment Control 
(α=.45) 
*Nothing can be done to improve my CTRF Low Cronbach alpha 
reliability  I believe medications can help my fatigue get better 
The negative effects of my CTRF can be prevented or avoided 
*There is nothing which can help my CTRF 
**My doctor knows that I have CTRF 
**I asked my doctor if there are any medicines or treatments for my 
CTRF 
Personal Control **What I do has no effect on my CTRF High IIC  
**If I could sleep more, my CTRF would get better Alpha increased with 
deletion from scale **I take naps during the day for my CTRF 
**I make sure I sleep at least 8 hours every night 
**There are things I can do to make my CTRF better High IIC 
**There is nothing I can do to make my CTRF better High IIC 
**I have asked others like family or friends for help with my CTRF Low IIC 
Symptom 
Coherence 
My CTRF is a mystery to me High IIC 
I know why I have CTRF High IIC 
Emotional 
Representation 
When I think about my CTRF I get upset High IIC 
**My CTRF makes me feel sad High IIC 
**I ignore my CTRF as much as I can Low IIC 
**I wish my CTRF would just go away Low IIC 
Positive 
Consequences 
**Having CTRF helps me realize what is really important in my life Low IIC 
* Item retained in Personal Control subscale 
** Investigator developed item 
IIC=inter-item correlation (Low IIC<.4; High IIC>.7) 
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Specific Aim #2 Describe the construct validity of the CTRFRep scale 
Hypothesis 3a: The CTRFRep Identity subscale will show a significant difference 
between the symptoms experienced subscale, and those symptoms associated with CTRF.  
In order to test this hypothesis, a paired-samples t-test was done to compare the 
mean number of symptoms reported by subjects (mean=14.86 (SD=5.33)) with the mean 
number of symptoms attributed as being related to or contributing to their CTRF 
(mean=11.53 (SD=5.70)). This test statistic was significant (t=-6.66; df=35; 2-tailed sig. 
p<0.000). This result supports the hypothesis that there is a significant difference between 
the two means. The relatively large number of symptoms that subjects rated as being 
related to or contributing to CTRF is perhaps surprising. However, as shown in Table 12, 
the scale includes several symptoms that are perhaps similar to fatigue or commonly 
related to fatigue. Further analysis with a larger sample will be necessary in order to 
examine the contribution of these additional symptoms to the subjects’ CTRF experience. 
Hypothesis 3b: CTRFRep subscales mediate the relationship between CTRF 
intensity and CTRF distress. 
In order to test this hypothesis a correlation matrix of all the variables in the study 
was evaluated for highly correlated variables. Table 32 shows the results of that analysis. 
Fatigue distress as measured by the CRFDS is the dependent variable in the regression 
analysis. Evaluation of the histogram of the CRFDS showed a bimodal distribution. In 
order to assess the fitness of the variable for linear regression, a normality test was done 
using the EXPLORE command in SPSS (Field, 2009; Sage Publications Limited & Field, 
2009). The results of this analysis showed that the distribution of CRFDS scores differs 
  
  
 
Table 32. 
 
Correlation Matrix of Study Variables 
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POMS Fatigue/Inertia  0.87** 0.76** 0.69** 0.76** 0.69** 0.53** -0.31 0.63** 0.65** -0.08 -0.26 -0.25 0.67** 0.82** 0.79** 
MFI General Fatigue 0.90**  0.78** 0.64** 0.66** 0.70** 0.45** -0.49** 0.54** 0.60** -0.11 -0.41* -0.25 0.49** 0.63** 0.66** 
MFI Physical Fatigue 0.74** 0.80**  0.85** 0.74** 0.64** 0.45** -0.41* 0.57** 0.55** 0.02 -0.29 -0.33* 0.51** 0.67** 0.68** 
MFI Reduced Activity 0.70** 0.68** 0.81**  0.69** 0.43** 0.30 -0.22 0.63** 0.49** -0.02 -0.30 -0.40* 0.35* 0.57** 0.60** 
MFI Reduced Motivation 0.71** 0.65** 0.71** 0.70**  0.57** 0.59** -0.40** 0.53** 0.49** -0.11 -0.38* -0.32* 0.63** 0.82** 0.74** 
MFI Mental Fatigue 0.71** 0.71** 0.62** 0.46** 0.58**  0.53** -0.39* 0.29 0.39* -0.18 -0.17 -0.02 0.48** 0.68** 0.70** 
PANAS Negative Affect 0.66** 0.60** 0.53** 0.40** 0.58** 0.57**  -0.41* 0.23 0.37* 0.04 -0.09 -0.19 0.51** 0.70** 0.51** 
PANAS Positive Affect -0.32* -0.47** -0.39** -0.27 -0.40** -0.44** -0.38**  -0.35* -0.21 0.18 0.42* 0.34* -0.30 -0.35* -0.25 
CTRFRep Acute vs. Chronic Timeline   0.52** -0.16 -0.37* -0.38* 0.49** 0.53** 0.51** 
CTRFRep Consequences   0.05 -0.34* -0.34* 0.71** 0.58** 0.74** 
CTRFRep 
Positive Consequences   0.06 -0.10 -0.17 -0.19 -0.11 
CTRFRep 
Personal Control   0.35* -0.20 -0.14 -0.10 
CTRFRep Symptom Coherence   -0.16 -0.19 -0.23 
CTRFRep Emotional Representation   0.73** 0.74** 
CESD Depression 0.86** 0.71** 0.71** 0.61** 0.77** 0.72** 0.76** -0.37*   0.87** 
N=36 for top half of matrix (fatigued subjects only) 
N=47 for bottom half of matrix (all subjects) 
*  Correlation is significant at the 0.05 level (2-tailed) 
** Correlation is significant at the 0.01 level (2-tailed) 
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significantly from the normal distribution (Shapiro-Wilk statistic 0.91; df 36; p=0.005). 
Because one of the assumptions of linear regression is normality of the dependent 
variable, the CRFDS variable was recoded in to two different groups (low distress<3.7 
and high distress>=3.7) and logistic regression was used to test the mediation models.  
Because of the small sample size (N=36), the recommendation is to use a 
maximum of three variables in the logistic regression. To select a measure of CTRF 
intensity to use for the logistic regressions, the correlation matrix in Table 32 was 
evaluated for a measure that was not highly correlated with the variables to be controlled 
for in the logistic regression (negative affect and CES-D). The F_POMS-sf is highly 
correlated (r>=.79) with both of these variables. The author of the MFI-20 recommends 
that the General Fatigue subscale be used if choosing only one score to use in analyses 
(Smets, 2002). The MFI General Fatigue subscale was less highly correlated with the 
CES-D and negative affect (r<=.66). Therefore, the General Fatigue subscale of the MFI-
20 was selected for use as the measure of fatigue intensity in the logistic regression. 
In an initial round of logistic regression analyses, the CES-D was entered along 
with the PANAS NA and the general fatigue subscale for fatigue intensity. When these 
regressions were analyzed, there was no significant effect of fatigue intensity on fatigue 
distress. After consulting with a statistician, the CES-D was identified as being too highly 
correlated with the CRFDS (r=.87). This resulted in an issue with multicollinearity and 
the suggestion was to eliminate the CES-D from the logistic regression analyses and 
continue with negative affect and the general fatigue scale.  
After these preliminary analyses, the logistic regressions were computed as 
described below.  
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Model 1: The PANAS was entered into the analysis as an independent variable 
(IV). Table 33 summarizes the results of this analysis 
Table 33. 
 
Model 1 Logistic Regression Results 
 
 95% CI for Odds Ratio 
Entered β(SE) Wald (df) Exp(β) Lower Upper 
Negative Affect 0.14*(0.06) 4.99(1) 1.15 1.02 1.30 
Constant -2.81(1.30) 4.71(1) 0.06  
 
Note: R2=.13 Hosmer & Lemeshaw; .15=Cox &Snell; .20=Nagelkerke. Model χ2(1)=5.81 p=.016 *p=.026 
 
Model 2: The PANAS was entered into the analysis as an IV (Block 1) and CTRF 
intensity was entered as an IV (Block 2), with CTRF distress entered as the DV. Table 34 
summarizes the results of the analysis. As is shown in the model, the Odds Ratio for 
CTRF intensity is significant (p=.014). This can be interpreted as showing that for every 
1-point increase in the score for CTRF intensity, the odds of being in the high distress 
group increase by 1.33. The significance level for CTRF intensity is the item of interest 
when testing mediation. In future models, if the significance of CTRF intensity is 
decreased after adding a variable, the variable added can be said to mediate the 
relationship between CTRF intensity and CTRF distress – after controlling for Negative 
Affect. 
Table 34. 
 
Model 2 Logistic Regression Results 
 
 95% CI for Odds Ratio 
Entered β(SE) Wald (df) Exp(β) Lower Upper 
Negative Affect 0.07 (.07) 0.91 (1) 1.07 .931 1.229 
CTRF Intensity 0.29* (.12) 6.04 (1) 1.33 1.060 1.667 
Constant -5.07 (1.79) 8.05 (1) 0.01  
 
Note: R2=.39 Hosmer & Lemeshaw; .32=Cox &Snell; .43=Nagelkerke. Model χ2(2)=14.02 p=.001 *p=.014 
  
 85 
 
 Model 3: Mediation model – PANAS entered as an IV (Block 1) then CTRF 
intensity as an IV (Block 2), CTRFRep subscales (Block 3) and CTRF distress as the DV. 
Because of the small sample size, only one CTRFRep subscale could be entered into 
analysis at a time. Therefore, multiple logistic regressions were performed (i.e. one 
logistic regression for each CTRFRep subscale). This leads one into the area of multiple 
comparisons, which is problematic. Although regressions were performed with each 
CTRFRep subscale, tabular results will be reported only for those subscales that were 
significant or nearly significant (i.e., p value for CTRF intensity approached non-
significance) mediators in the relationship between CTRF intensity and CTRF distress. 
 The four CTRFRep subscales which performed as mediators of the relationship 
between CTRF intensity and CTRF distress are the Identity, Acute vs. Chronic Timeline 
(partial mediator), Consequences and Emotional Representation (partial mediator). 
Tables 35-38 present the results of the logistic regressions for these subscales. 
Table 35. 
 
Model 3 Logistic Regression Results for CTRFRep Identity Subscale 
 
 95% CI for Odds Ratio 
Entered β(SE) Wald (df) Exp(β) Lower Upper 
Negative Affect 0.02 (0.08) 0.08 (1) 1.02 0.88 1.19 
CTRF Intensity 0.22* (.12) 3.30 (1) 1.25 0.98 1.59 
CTRFRep Identity 0.14 (.10) 1.96 (1) 1.15 0.95 1.41 
Constant -4.95 (1.81) 7.43 (1) 0.01  
 
Note: R2=.48 Hosmer & Lemeshaw; .36=Cox &Snell; .48=Nagelkerke. Model χ2(3)=16.11 p=.001 *p=.070 
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Table 36. 
 
Model 3 Logistic Regression Results for CTRFRep Timeline Acute vs. Chronic Subscale 
 
 95% CI for Odds Ratio 
Entered β(SE) Wald (df) Exp(β) Lower Upper 
Negative Affect 0.07 (0.07) 1.02 (1) 1.08 0.93 1.24 
CTRF Intensity 0.26* (.13) 4.25 (1) 1.30 1.01 1.66 
CTRFRep Acute vs. Chronic Timeline 0.06 (.01) 0.33 (1) 1.06 0.87 1.28 
Constant -5.53 (2.01) 7.57 (1) 0.04  
 
Note: R2=.40 Hosmer & Lemeshaw; .33=Cox &Snell, .44=Nagelkerke. Model χ2(30=14.36 p=.002 *p=.039 
 
Table 37. 
 
Model 3 Logistic Regression Results for CTRFRep Consequences Subscale 
 
 95% CI for Odds Ratio 
Entered β(SE) Wald (df) Exp(β) Lower Upper 
Negative Affect 0.06 (0.08) 0.48 (1) 1.06 0.91 1.24 
CTRF Intensity 0.17* (.13) 1.68 (1) 1.19 0.92 1.54 
CTRFRep Consequences 0.31 (.14) 5.06 (1) 1.36 1.04 1.79 
Constant -8.99 (2.95) 9.33 (1) 0.00  
 
Note: R2=.72 Hosmer & Lemeshaw; .44=Cox &Snell; .59=Nagelkerke. Model χ2(3)=20.91 p=.000 *p=.20 
 
Table 38. 
 
Model 3 Logistic Regression Results for CTRFRep Emotional Representation Subscale 
 
 95% CI for Odds Ratio 
Entered β(SE) Wald (df) Exp(β) Lower Upper 
Negative Affect 0.06 (0.09) 0.01 (1) 1.01 0.85 1.19 
CTRF Intensity 0.25* (.13) 3.83 (1) 1.28 1.00 1.65 
CTRFRep Emotional Representation 0..28 (.14) 4.06 (1) 1.33 1.01 1.74 
Constant -6.96 (2.32) 8.97 (1) 0.00  
 
Note: R2=.63 Hosmer & Lemeshaw; .42=Cox &Snell; .55=Nagelkerke. Model χ2(3)=19.32 p=.000 *p=.050 
 
 As shown in these tables, the significance level of CTRF intensity approaches or 
reaches a non-significant p value when these four CTRFRep subscales are added to the 
logistic regressions. This indicates that these scales act as mediators of the relationship 
between CTRF intensity and CTRF distress and supports the construct validity of the 
CTRFRep as well as the model presented in Figure 1. The CTRFRep scales that did not 
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perform as mediators were the Symptom Coherence, Personal Control, and Positive 
Consequences. Further observation and analysis of these subscales will be necessary in 
order to understand their relationship to CTRF intensity and CTRF distress. 
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CHAPTER 5: DISCUSSION 
Introduction 
This chapter begins with a restatement of the purpose of the study and continues 
with an examination of the CTRFRep scale and its subscales. The instrument as a whole 
is discussed. Then the results of each subscale are addressed and the implications for 
current knowledge and future areas of research are discussed.  
Discussion 
The purpose of this study was to report on the development of a measure of 
CTRFRep and describe its psychometric properties in patients undergoing radiation 
treatment for cancer. The CTRFRep is designed to measure cancer treatment-related 
fatigue representation, a key component of the model of the fatigue experience depicted 
in Figure 1. This figure is based upon Leventhal’s CSMSR. The main findings of the 
study were: the subscale factor analyses were not definitive, most likely due to the small 
sample size; the internal consistency reliability of the majority of the CTRFRep subscales 
was adequate; and the construct validity of four subscales was supported by mediation 
models tested using the relationships in Figure 1. 
In terms of the utility of the instrument, patients expressed little difficulty in 
understanding the CTRFRep. In evaluating the CTRFRep using the analysis described, it 
was found that the majority of the items modified from the original IPQ-R performed 
well. Since the IPQ-R is based on the CSMSR, these findings tend to support the 
theoretical consistency of the CTRFRep. Items that were added by the investigator or at 
the suggestion of the content experts did not perform as well. As a result of the analysis 
of this study, at least 22 items (see Table 31) will be deleted from future versions of this 
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scale, and it is expected that future research will allow for the deletion of additional 
items.  
The results of the study indicate that parts of the CTRFRep may be a reliable and 
valid measure of representational beliefs about CTRF, whereas other parts may not. Two 
subscales (Treatment Control and Cyclical Timeline) from the original IPQ-R, on which 
the CTRFRep is based, did not show adequate internal consistency reliability. The small 
size of the sample may be an issue here. However, it is also possible that testing in a more 
homogeneous group of cancer patients (e.g., patients receiving chemotherapy) may result 
in improved internal consistency for the Cyclical Timeline subscale, as some 
chemotherapy patients in this study anecdotally reported that their fatigue was cyclical, 
and this is also seen in the literature (Mustian, Palesh, & Heckler, 2008).  
In terms of the Treatment Control subscale, the reasons for its poor performance 
as a subscale may also be related to the small sample size. However, there are other 
questions about the viability of this scale in terms of beliefs about the treatment of cancer 
treatment-related fatigue. Are patients aware of medications and treatments that can be 
used for CTRF? The literature suggests that exercise and balancing activities with rest 
may be useful treatments for CTRF. In what may be the largest gap between current 
empirical knowledge about CTRF and the CTRFRep instrument, the CTRFRep did not 
address activity, and had few questions focusing on sleep. In addition, treatment in 
general connotes something that is done to a person (e.g., radiation treatment) or given to 
a person (e.g., medication). There are some medical treatments (e.g., erythropoietin 
therapy) that are helpful for some patients with CTRF, but knowledge or beliefs about 
these treatments is not assessed in the CTRFRep. Finally, the most effective treatments 
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for CTRF may be things that the patient has to be guided toward or learn how to do for 
himself (e.g., balancing activities with rest and implementing an exercise program). 
While these are treatments with proven effectiveness (Berger, et al., 2009), they may not 
be intuitive for patients. In future versions of the CTRFRep, addressing beliefs about 
exercise and other activity may be necessary to understand patients’ representations of 
CTRF and its possible treatments. 
The Cause subscale of the CTRFRep showed that most subjects attributed having 
cancer itself or their cancer treatments as causes of their CTRF, followed by stress, diet, 
and aging. The factor analysis of the cause subscale was not successful. According to 
Moss-Morris and Siversten (2009), a sample size of about 85 is necessary to contemplate 
a successful factor analysis of the causal items of the IPQ-R. Given that the CTRFRep 
has more items in its Cause subscale than the IPQ-R, the problems with factor analysis at 
a sample size of 36 are not surprising. Continued data collection should result in a sample 
size that is adequate to factor the Cause subscale. 
A surprising finding is the number of people (28% and 11%) who said that 
heredity and poor medical care in their past were causes of their CTRF. In terms of face 
validity, these items could be more likely seen as causes of cancer itself, rather than 
CTRF. In terms of administration of the questionnaire, the instructions for this section 
need to be clarified for both face-to-face and possible future self-administration to stress 
the notion that the interest is in subjects’ beliefs about causes of their CTRF, not their 
cancer. The Cause subscale has a low Cronbach alpha however, given the independence 
of the items on the scale and the fact that it likely contains multiple factors this is not 
surprising. It is not appropriate to interpret alpha reliability on such a scale. Following the 
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accrual of additional subjects and factor analysis of the Cause subscale, the Cronbach 
alpha of those subscales (e.g., causal beliefs surrounding treatment, causal beliefs 
surrounding emotional factors) could be properly interpreted for these subscales. 
The Identity subscale consists of a list of symptoms patients have experienced 
since they began having CTRF that they believe are related to their CTRF. This subscale 
performed fairly well, in both the discriminant validity of the scale and in testing of 
mediation discussed below. The most common symptoms were those not listed on the 
original IPQ-R but suggested by the content experts. Some of the more frequently 
endorsed symptoms are very similar to fatigue (e.g., lack of energy, loss of strength) but 
others are unique items (e.g., feeling blue, poor concentration) that may add to the 
information base for helping patients with their CTRF. One thing that is lacking in the 
current version of the CTRF is a question about what the most salient symptom(s) are for 
the patient. This question is present in the Symptom Representation Questionnaire 
(Donovan, Ward, Sherwood, & Serlin, 2008). A question of this nature could be used to 
focus attention on areas deemed the most important by the patient in future research.  
Factor analysis of the CTRFRep subscales with adequate reliability (Acute vs. 
Chronic Timeline, Consequences, Positive Consequences, Personal Control, Symptom 
Coherence, and Emotional Representation) could not be completed successfully. There is 
definitely an issue with sample size here, and it is hoped that a sample size of 100 will be 
adequate to test the remaining 34 items in these subscales. Interestingly, in general the 
individual items that performed well in reliability testing were those that came from the 
original IPQ-R. The items added at the suggestion of content experts or by this 
investigator did not perform well in the reliability analysis. This finding may support the 
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factor structure of the CTRFRep being similar to that of the IPQ-R, save for the subscales 
that did not have adequate reliability.  
The model of the CTRF experience presented in Figure 1 hypothesizes that CTRF 
representation mediates the relationship between CTRF intensity and CTRF distress. 
Thus, construct validity of the CTRFRep scale was tested using the mediation model 
presented in Figure 1. The distribution of the outcome variable of CTRF distress differed 
significantly from the normal distribution. The bi-modal distribution of CTRF distress 
suggested that it may be wise to dichotomize the variable, and so it was dichotomized at 
the median value of 3.8. This resulted in two samples, one of which could be called “no 
distress or mild distress,” the other “moderate to severe distress.” Dichotomization of the 
dependent variable decreased the variability of the sample, and changed the regressions 
performed from linear to logistic regressions.  
In spite of the use of logistic regression, four of the subscales of the CTRFRep at 
least partially mediated the relationship between CTRF intensity and CTRF distress. The 
Identity, Acute vs. Chronic Timeline, Consequences, and Emotional Representation 
subscales acted as mediating variables in the logistic regressions. The strongest mediator 
was the Consequences subscale, while the least significant partial mediator was the Acute 
vs. Chronic Timeline subscale. Interestingly, the mediating subscales had higher, 
statistically significant bivariate correlation with CTRF distress, and all of the mediating 
subscales had significantly different means between the low distress and high distress 
groups when compared using a t-test. The subscales that did not act as mediators include 
the Positive Consequences, Personal Control, and Symptom Coherence subscales. None 
 93 
 
of the non-mediating variables had a significant bivariate correlation or significantly 
different means when examined using a t-test.  
During preliminary analysis, it was discovered that the CES-D was highly 
correlated with both the measures of CTRF intensity and CTRF distress. This correlation 
was such that it created a problem with multicollinearity. Therefore, in spite of wanting to 
control for both depression and negative affect in the regressions, only negative affect 
could be included in the regression equations. In addition, the small sample size limited 
the number of independent variables in the regressions to a maximum of three. Therefore, 
rather than looking at the combined effect of the CTRFRep subscales, each of the 
subscales had to be examined individually. A larger sample size could allow inclusion of 
more of the CTRFRep subscales in the regression analyses.  
Limitations 
There are several limitations to the current study. First, the non-probability 
convenience sample limits the generalizability of the findings. The sample of 48 patients 
was a small sample for analyses of this sort. The recruitment clinic was located in a 
teaching hospital in the Midwest. Although indigent patients are also treated at this clinic, 
the sample included few minority subjects. This limits the generalizability of these 
findings to non-Latino, white patients receiving radiation treatment for cancer.  
The cross-sectional, descriptive design of the study is appropriate for the scope of 
this study, which was an introductory test of the CTRFRep instrument. However, this 
design limits the ability to state any causal relationships between variables related to 
changes over time. When compared to other studies, the use of a model incorporating 
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logistic regression and a mediation model to test construct validity is a more robust 
method than comparison of Pearson correlation coefficients. 
The results of this study show that depression is highly correlated with the 
outcome variable of CTRF distress. This limited the scope of the logistic regressions to 
controlling for negative affect alone, rather than the plan to control for negative affect 
and depression. The small sample size limited the use of independent variables in the 
logistic regression to three per analysis. This resulted in the use of multiple comparisons, 
which is problematic because it effectively increases the p-value. With more variables in 
the logistic regression, there may have been fewer CTRFRep variables that were 
significant mediators of the relationship between CTRF intensity and CTRF distress.  
In summary, preliminary testing with this small sample size shows some support 
for the relationships hypothesized in Figure 1. The CTRFRep has four subscales that 
appear to be reliable and valid (Identity, Acute vs. Chronic Timeline, Consequences, and 
Emotional Representation). The Cause subscale appears to function well but will need to 
be tested using factor analysis before any relationships between it and the other 
constructs in the model can be tested. Two subscales failed reliability testing in this 
sample, (Treatment Control and Cyclical Timeline). Answers as to whether this is an 
issue with sample size or the underlying constructs as they related to cancer treatment-
related fatigue will need to await further testing. 
Directions for Future Research 
The results of this study hold direct implications for further research in the area of 
CTRF and for the CTRFRep instrument. In the immediate term, data collection should 
continue in order to obtain a sample size adequate for factor analysis. The continuing 
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goal is to develop a parsimonious, theoretically consistent instrument to measure CTRF 
representation. The methodology of the current study is labor intensive, and future 
research should take this into account and attempt to develop a simpler means of 
conducting the research.  
Plans for future research include testing the CTRFRep in other populations of 
cancer patients in order to understand the differences in CTRF representational beliefs 
across other types of cancer treatment. Further development and testing of the 
relationships hypothesized in Figure 1 is necessary so that healthcare providers can have 
a better understanding of patients’ beliefs thoughts and emotions surrounding the 
experience of CTRF. This information, once acquired, can be used to drive tailored 
interventions for particular beliefs about CTRF in order to improve patient outcomes.  
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IUPUI and CLARIAN INFORMED CONSENT STATEMENT FOR 
 
Psychometric testing of the Cancer Treatment-Related Fatigue Representation Scale 
(CTRFRep) in patients receiving radiation treatment for cancer 
 
 
You are invited to participate in a research study that tests a survey tool for patients with 
cancer and fatigue. You were selected as a possible subject because you are getting 
radiation treatments for cancer. We ask that you read this form and ask any questions you 
may have before agreeing to be in the study.  
 
The study is being conducted by Janet Welch, DNS, RN, and Kristina M. Reuille, 
PhD(c), RN, of the Indiana University School of Nursing; and Dr. Higinia R. Cardenes, 
of the Department of Radiation Oncology, Indiana University School of Medicine. It is 
funded by the National Institute of Nursing Research through a National Research 
Service Award (NRSA) fellowship awarded to Ms. Reuille. 
 
STUDY PURPOSE 
 
The purpose of this study is to learn about new survey tool designed to help health care 
personnel understand patients’ beliefs, thoughts and emotions about having cancer 
treatment-related fatigue, or cancer treatment-related fatigue representation. Many 
patients who have radiation treatment for cancer have fatigue during or after their 
treatment. If the new survey tool accurately measures cancer treatment-related fatigue 
representation, this study will help us understand more about patient’s experiences with 
cancer treatment-related fatigue.  
 
NUMBER OF PEOPLE TAKING PART IN THE STUDY: 
 
If you agree to participate, you will be one of 100 subjects who will be participating in 
this research. 
 
PROCEDURES FOR THE STUDY: 
 
If you agree to be in the study, you will do the following things: 
 
• You will answer questions in a one-time survey interview that takes about 25-45 
minutes to finish. 
• This interview will take place in a private location at the Radiation Oncology 
Clinic in the Indiana University Cancer Center. 
• The types of questions in the survey include: “I think I do a lot in a day;” My 
cancer-related fatigue changes a great deal from day to day;” and “The fatigue or 
tiredness I am having causes me distress because it makes me stay at home more.” 
• There are no right or wrong answers to the questions in the survey. 
 
If you choose to participate in this study, the timeline of the study will be as follows: 
 
• You will complete your radiation treatments here in the Radiation Oncology 
Clinic 
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• Near the time of your last treatment, you will schedule a follow-up appointment 
with your doctor. 
• This follow-up appointment usually happens about four weeks after your 
treatment is finished. 
• During this follow-up appointment you will meet with your doctor and complete 
the interview for this study. 
 
RISKS OF TAKING PART IN THE STUDY: 
 
While on the study, the risks or discomforts are: 
 
There are no physical risks to taking part in this study.  
The risks of completing the survey are being uncomfortable answering the questions.  
There is a risk of possible loss of confidentiality. 
 
The following measures will be taken to minimize these risks: 
 
While completing the survey, you can tell the interviewer that you feel uncomfortable or 
do not care to answer a particular question. 
Every attempt will be made to protect your confidentiality and ensure that only members 
of the research team will be aware of your identity.  
 
BENEFITS OF TAKING PART IN THE STUDY: 
 
There is no direct benefit to participating in the study. The benefits to participation that 
are reasonable to expect are: 1) satisfaction gained from sharing your thoughts and 
feelings about your experience with fatigue and/or 2) cancer treatment and knowledge 
that your participation may help other patients like you in the future. 
 
ALTERNATIVES TO TAKING PART IN THE STUDY: 
 
Instead of being in the study, you have these options:  
 
You may choose not to be in the study. 
 
CONFIDENTIALITY 
 
Efforts will be made to keep your personal information confidential. We cannot 
guarantee absolute confidentiality. Your personal information may be disclosed if 
required by law. Your identity will be held in confidence in reports in which the study 
may be published and databases where results may be stored. 
 
Organizations that may inspect and/or copy your research records for quality assurance 
and data analysis include groups such as the study investigator and his/her research 
associates, the IUPUI/Clarian Institutional Review Board or its designees, the study 
sponsor, the National Institute of Nursing Research, and (as allowed by law) state or 
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federal agencies, specifically the Office for Human Research Protections (OHRP), and 
the National Institutes of Health (NIH) who may need to access your medical and/or 
research records. 
 
COSTS 
 
There are no monetary costs for subjects participating in this study. If you choose to 
participate in the study, the follow-up appointment may be up to 45 minutes longer than 
normal because you will be completing the interview at this appointment. This will not 
affect the scheduling of your follow-up appointment.  
 
PAYMENT 
 
You will not receive payment for taking part in this study 
 
 
CONTACTS FOR QUESTIONS OR PROBLEMS 
 
For questions about the study or a research-related injury, contact the researcher Kristina 
M. Reuille PhD(c), RN at 317-295-0083 or 317-439-5743 or Janet Welch, DNS, RN at 
317-274-0024 or 317-294-8091. If you cannot reach the researcher during regular 
business hours (i.e. 8:00AM-5:00PM), please call the IUPUI/Clarian Research 
Compliance Administration office at (317) 278-3458 or (800) 696-2949. After business 
hours, please call Ms. Reuille at 317-295-0083 or 317-439-5743. 
 
In the event of an emergency, you may contact Ms. Reuille at 317-295-0083 or 317-439-
5743.  
 
For questions about your rights as a research participant or to discuss problems, 
complaints or concerns about a research study, or to obtain information, or offer input, 
contact the IUPUI/Clarian Research Compliance Administration office at (317) 278-3458 
or (800) 696-2949. 
 
VOLUNTARY NATURE OF STUDY 
 
Taking part in this study is voluntary. You may choose not to take part or may leave the 
study at any time. Leaving the study will not result in any penalty or loss of benefits to 
which you are entitled. Your decision whether or not to participate in this study will not 
affect your current or future relations with the Indiana University Cancer Center 
Radiation Oncology Clinic. 
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SUBJECT’S CONSENT 
 
In consideration of all of the above, I give my consent to participate in this research 
study.  
 
I will be given a copy of this informed consent document to keep for my records. I agree 
to take part in this study. 
 
 
Subject’s Printed Name:  
 
 
 
 
Subject’s Signature:                                                                                 Date:  
             
(must be dated by the subject) 
 
 
 
Printed Name of Person Obtaining Consent:  
 
 
 
Signature of Person Obtaining Consent:                                                  Date:  
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Introduction:  You have the right to decide who may review or use your Protected Health Information 
("PHI").  The type of information that may be used is described below. When you consider taking part in a 
research study, you must give permission for your PHI to be released from your doctors, clinics, and 
hospitals to the research team, for the specific purpose of this research study.   
 
What does this authorization relate to? This authorization relates to the following study: 
 
Janet Welch, DNS, RN 
PRINCIPAL INVESTIGATOR (in charge of 
Research Team) 
 
NAME OF RESEARCH PARTICIPANT 
 
STREET ADDRESS 
IRB #0403-69B 
IRB PROTOCOL # 
SPONSOR  # NINR/ 1 F31 NR 008834-01 A1 
 
BIRTHDATE 
 
CITY, STATE & ZIP CODE 
 
What information will be used for research purposes? The PHI that will be used for research 
purposes may include some or all of your health records.  This includes, but is not limited to: information 
provided by you directly to the Research Team, hospital records and reports; admission histories, and 
physicals; X-ray films and reports; operative reports; laboratory reports; treatment and test results; 
immunizations; allergy reports; prescriptions; consultations; clinic notes; and any other medical or dental 
records needed by the Research Team. 
 
Specific Authorizations: I understand that this release also pertains to records concerning hospitalization 
or treatment that may include the categories listed below.  I have the right to specifically request that 
records NOT be released from my health care providers to the Research Team.  However, I understand that 
if I limit access to any of the records listed below, I may not be able to be in this research study. Check 
limitations, if any, below: 
 
  Mental health records   Sexually transmitted diseases 
  Psychotherapy Notes   Alcohol / Substance abuse 
  HIV (AIDS)   Other: _____________________________ 
 
Who will be allowed to release this information? 
I authorize the following persons, groups or organizations to disclose the information described in this 
Release of Information/Authorization for the above referenced research study: 
  Treating providers   Hospitals, clinics or other places where I have 
  received treatment 
  Other:    
  
  The Principal Investigator and the Research Staff 
 
Who can access your PHI for the study?  The people and entities listed above may share my PHI (or the 
PHI of the individual(s) whom I have the authority to represent), with the following persons or groups for 
the research study:  the Research Team, Institutional Review Board, Research Sponsor and its 
representatives, Research Organizations, the Department of Health & Human Services or other US or 
foreign government agencies as required by law, and to the Food and Drug Administration (FDA) or a 
person subject to the jurisdiction of the FDA in order to audit or monitor the quality, safety or effectiveness 
of the product or activity.  
 
The Research Team includes the Principal Investigator, his/her staff, research coordinators, research 
technicians and other staff members who provide assistance to the Research Team.  If there is a Research 
Sponsor(s), this shall include: The National Institute of Nursing Research and any Research 
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Organizations who provided assistance to the Research Sponsor(s) including, but not limited to: -
_______________________________.  
 
Expiration date of this Authorization:  This authorization is valid until the following date or event:     
 
  Specify Date ___/___/____    End of the Study    None 
 Other: ______________________  Indefinitely, or until such time as authorized by the  
            sponsor to destroy study documents   
 
 
Efforts will be made to ensure that your PHI will not be shared with other people outside of the research 
study.  However, your PHI may be disclosed to others as required by law and/or to individuals or 
organizations that oversee the conduct of research studies, and these individuals or organizations may not 
be held to the same legal privacy standards as are doctors and hospitals.  Thus, the Research Team cannot 
guarantee absolute confidentiality and privacy.   
 
I have the right: 
1. To refuse to sign this form.  Not signing the form will not affect my regular health care 
including treatment, payment, or enrollment in a health plan or eligibility for health care 
benefits.  However, not signing the form will prevent me from participating in the research 
study above. 
 
2. To review and obtain a copy of my personal health information collected during the study.  
However, it may be important to the success and integrity of the study that persons who 
participate in the study not be given access until the study is complete.  The Principal 
Investigator has discretion to refuse to grant access to this information if it will affect the 
integrity of the study data during the course of the study. Therefore, my request for 
information may be delayed until the study is complete.   
 
3. To cancel this release of information/authorization at any time.  If I choose to cancel this 
release of information/authorization, I must notify the Principal Investigator for this study in 
writing at: Janet Welch, DNS, RN at the Indiana University School of Nursing, 1111 
Middle Drive, NU 407, Indianapolis, IN 46202.  However, even if I cancel this release of 
information/authorization, the Research Team, Research Sponsor(s) and/or the Research 
Organizations may still use information about me that was collected as part of the research 
project between the date I signed the current form and the date I cancel the authorization.  
This is to protect the quality of the research results.  I understand that canceling this 
authorization may end my participation in this study.  
 
4. To receive a copy of this form. 
 
I have had the opportunity to review and ask questions regarding this release of information/authorization 
form.  By signing this release of information/authorization, I am confirming that it reflects my wishes. 
 
Printed name of Individual/Legal Representative 
 
Signature of Individual/Legal Representative 
 
Date 
*If signed by a legal representative; state the relationship and identify below the authority to act on behalf 
of the individual’s behalf. 
 
*Individual is:   a Minor        Incompetent       Disabled 
  Deceased 
*Legal Authority:      
 149 
  Custodial Parent  Legal Guardian  Executor of Estate of the 
Deceased  
  Power of Attorney Healthcare  Authorized Legal Representative    Other: 
___________   
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